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Summary	  	  	  
The Warburg effect, the metabolic reprogramming of cancer cell toward aerobic 
glycolysis, occurs as a consequence of transformation carried out by several 
oncogenes. Aerobic glycolysis represents a metabolism particularly suited for cell 
growth, because it couples energy production to availability of chemical 
precursors for the biosynthesis of the main macromolecules (dNTPs, aminoacids 
and lipids). Metabolic reprogramming is usually considered as a simple 
phenotypic endpoint that occurs as a consequence of tumor formation. Growing 
evidences indicate, however, that metabolism on its turn can support oncogenic 
signaling to foster tumor malignancy. During my PhD, I studied how glucose 
metabolism regulates gene transcription, and found an unexpected link with 
YAP/TAZ, key transcription co-factors regulating organ growth, tumor cell 
proliferation and aggressiveness. Glucose metabolism and a sustained flux of 
glucose through aerobic glycolysis support YAP/TAZ transcriptional activity, 
whereas treatments that reprogram cellular metabolism away from aerobic 
glycolysis induce corresponding reductions in YAP/TAZ activity. Accordingly, 
glycolysis is required to sustain YAP/TAZ pro-tumorigenic functions:  inhibition 
of glucose metabolism, or knockdown of key enzymes of glycolysis, hampers 
YAP/TAZ-induced tumorigenic phenotypes in breast cancer cells, such as 
proliferation, clonogenic activity and self-renewal properties. In addition, 
YAP/TAZ are required for the full deployment of glucose growth-promoting 
activity, in keeping with the idea of oncogenic signaling at the service of a 
metabolic pathway. Mechanistically we found that Phosphofructokinase 1 
(PFK1), the enzyme regulating the first committed step of glycolysis, binds the 
YAP/TAZ transcriptional co-factors TEADs and promote their functional and 
biochemical cooperation with YAP/TAZ. Strikingly, this regulation is conserved 
in Drosophila, where phosphofructokinase is required for tissue overgrowth 
promoted by Yki, the fly homologue of YAP/TAZ. Moreover, gene expression 
regulated by glucose metabolism in breast cancer cells is strongly associated in a 
large dataset of primary human mammary tumors with YAP/TAZ activation and 
with the progression toward more advanced and malignant stages. These findings 
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suggest that aerobic glycolysis endows cancer cells with particular metabolic 
properties and, at the same time, sustains transcription factors with potent pro-
tumorigenic activities such as YAP/TAZ. These results were published in1 and 
reviewed in2,3. 
This study highlighted the notion that YAP/TAZ are atypical oncogenic 
molecules that, rather than being activated by genetic events, lay downstream of 
metabolic reprogramming. However, which are the genes and cellular 
mechanisms by which YAP/TAZ sustain cell proliferation remains largely 
unknown. Recently, extensive gene expression profiling of cancer cells indicate 
that YAP/TAZ regulate a series of genes and programs linked to cell-cycle 
regulation, including genes involved in nucleotide metabolism. During the third 
year of my PhD, I have explored whether YAP/TAZ sustain nucleotide 
metabolism, and whether this is relevant in the context of oncogene-induced 
senescence (OIS) and cancer cell proliferation. Preliminary data suggest an 
important role of nucleotide metabolism downstream of YAP/TAZ for the control 
of cell proliferation and resistance to cellular senescence. 
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Summary	  (Italian	  version)	  
	  
L’effetto Warburg, ovvero la riprogrammazione del metabolismo di cellule 
tumorali verso la glicolisi aerobia, si instaura come conseguenza della 
trasformazione oncogenica. La glicolisi aerobia rappresenta un tipo di 
metabolismo particolarmente appropriato per la crescita delle cellule, perché 
accoppia la produzione di energia alla disponibilità di precursori chimici per la 
biosintesi delle principali macromolecole (dNTP, aminoacidi e lipidi). La 
riprogrammazione del metabolismo viene spesso considerata come una semplice 
conseguenza fenotipica della formazione del tumore. Tuttavia, evidenze crescenti 
indicano che variazioni nel metabolismo possono esse stesse supportare la 
segnalazione oncogenica e favorire la malignità tumorale. Durante il mio 
dottorato, ho indagato come il metabolismo del glucosio regolasse la trascrizione 
genica, portando alla luce un collegamento inaspettato tra il metabolismo del 
glucosio e YAP/TAZ, co-fattori trascrizionali chiave per regolare la crescita degli 
organi, la proliferazione cellulare maligna e l’aggressività dei tumori. Il 
metabolismo del glucosio e il suo flusso sostenuto attraverso la glicolisi aerobia 
supportano l’attività trascrizionale di YAP/TAZ, mentre trattamenti che 
riprogrammano il metabolismo cellulare, riducendo la glicolisi aerobia, inducono 
una corrispondente riduzione della loro attività. In accordo con i precedenti 
risultati, la glicolisi è richiesta per sostenere le funzioni pro-tumorigeniche di 
YAP/TAZ: l’inibizione del metabolismo del glucosio, o la soppressione 
dell’espressione di enzimi chiave della glicolisi, ostacola fenotipi tumorigenici 
indotti da YAP/TAZ, tra i quali la proliferazione, l’attività clonogenica e le 
proprietà di auto-rinnovamento di cellule del cancro al seno. Inoltre, YAP/TAZ 
sono richiesti affinchè il glucosio promuova a pieno la crescita cellulare, nell’idea 
di una segnalazione oncogenica al servizio del metabolismo. A livello del 
meccanismo molecolare, abbiamo scoperto che l’enzima fosfofruttochinasi 1 
(PFK1), che regola la prima vera reazione della glicolisi, lega i TEAD, co-fattori 
trascrizionali di YAP/TAZ, promuovendo così la loro cooperazione funzionale e 
biochimica con YAP/TAZ. Sorprendentemente, questa regolazione è conservata 
anche in Drosophila, dove la fosfofruttochinasi è richiesta per la crescita abnorme 
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dei tessuti promossa da Yki, omologo di YAP/TAZ nel moscerino. Inoltre, nelle 
cellule del cancro al seno, l’espressione genica regolata dal metabolismo del 
glucosio è fortemente associata all’attivazione di YAP/TAZ e ad una progressione 
tumorale maligna avanzata. Queste osservazioni suggeriscono che la glicolisi 
aerobia fornisca particolari proprietà metaboliche alle cellule cangerogene e, allo 
stesso tempo, sostenga fattori di trascrizione che hanno una potente attività 
tumorigenica, come YAP/TAZ. Questi dati sono stati pubblicati in1 e riesaminati 
in2,3. 
Questo studio sottolinea come YAP/TAZ siano oncoproteine atipiche in quanto, 
invece di essere attivate da eventi genetici, si collocano a valle di una 
riprogrammazione del metabolismo. Rimane ancora tuttavia oscuro quali siano i 
geni e i meccanismi cellulari tramite i quali YAP/TAZ sostengano la 
proliferazione cellulare. Recentemente, profili di espressione genica, effettuati 
estensivamente su cellule tumorali, hanno evidenziato che YAP/TAZ regolano un 
insieme di geni e programmi collegati con la regolazione del ciclo cellulare, 
inclusi geni coinvolti nel metabolismo dei nucleotidi. Durante il terzo anno del 
mio dottorato, ho analizzato se YAP/TAZ sostenessero il metabolismo dei 
nucleotidi, e se questo fosse rilevante nel contesto della senescenza indotta da 
oncogeni (OIS) e della proliferazione delle cellule tumorali. Dati preliminari 
suggeriscono un ruolo significativo del metabolismo dei nucleotidi a valle di 
YAP/TAZ, sia nel controllo della proliferazione che nella resistenza alla 
senescenza cellulare. 
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Introduction	  	  	  
GLUCOSE	  METABOLISM	  
 
Glucose is an essential source of energy and carbon building blocks for animal 
cells, both considering the cellular and systemic levels. Once it enters in the cell 
through dedicated transporters, glucose is entrapped in the form of glucose-6-
phosphate (G6P) by hexokinase enzymes and primed for subsequent metabolic 
reactions: G6P can be metabolized through glycolysis and the Pentose Phosphate 
Pathway (PPP), or it can be stored as glycogen. If glucose is directed to catabolic 
processes, it can be used either to generate the ribose for nucleotide synthesis and 
reducing equivalents, through the PPP, or to generate chemical energy and other 
metabolic intermediates through glycolysis. These glycolytic intermediates 
provide a carbon source to a number of different anabolic processes, including the 
Hexosamine Biosynthetic Pathway (HBP), providing precursors for protein 
glycosylation, aminoacid and lipid precursors. Furthermore, glucose also 
significantly contributes to fuel the tricarboxylic acid (TCA) cycle and 
mitochondrial respiration, thereby ensuring the continuous and efficient 
production of energy in the form of ATP. Glucose and its derivatives are thus 
partitioned into several biosynthetic pathways, representing one main source of 
energy and, at the same time, providing essential chemical precursors for the 
biosynthesis of the main macromolecules required to build a cell. Indeed the 
regulation of glucose uptake and of its intracellular fate is crucial for cell 
physiology4.	  
 
GLYCOLYSIS	  
 
Glycolysis is a set of metabolic reactions that convert glucose to pyruvate and 
represents a major entry pathway for carbon atoms into cell metabolism. 
Glycolysis transforms glucose into chemicals that can be used either as precursors 
for anabolic processes (see above) and/or to sustain energy production, either 
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directly during glycolysis or by fuelling oxidative phosphorylation and 
mitochondrial respiration4. 
The sequence of biochemical reactions can be divided in two major phases: (1) an 
energy requirement step (consuming two molecules of ATP per glucose molecule) 
and (2) an energy production step (producing four ATPs per glucose). During the 
first phase, hexokinase (HK) enzymes phosphorylate glucose, thus entrapping 
G6P in the cell. G6P is then converted into fructose-6-phosphate (F6P) by 
phosphoglucose isomerase (GPI). The isomerization step is followed by a second 
energy-consuming reaction catalysed by phosphofructokinase 1 (PFK1), which 
converts F6P in fructose-1-6-bisphosphate (F1,6BP). Since G6P and F6P can be 
redirected to other metabolic processes, like the PPP and the HBP, the reaction 
carried out by PFK1 is the first truly dedicated step of glycolysis. Given its 
“gatekeeper” role, PFK1 is one of the most tightly regulated enzymes of 
glycolysis, being allosterically regulated by metabolites of glycolysis, of the TCA 
cycle and by the AMP/ATP ratio5. 
F1,6BP is then broken by fructose bisphosphate aldolase enzyme into two three-
carbon molecules: dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-
phosphate (G3P); DHAP is rapidly converted into G3P, which fuels the remaining 
reactions of glycolysis. So, two G3P molecules are produced per glucose, with the 
net consumption of two ATPs.  
During the second phase of glycolysis, G3P is converted to 1,3-
bisphosphoglycerate (1,3BPG) by glyceraldehyde 3-phosphate dehydrogenase to 
allow the production of a higher energy molecule. The reaction requires the 
reduction of NAD+ to NADH. In the last steps, two molecules of ATP are 
produced: one derives from the conversion of 1,3BPG into 3-phosphoglycerate 
(3PG), the other one from the two-step conversion of phosphoenolpyruvate (PEP) 
into pyruvate. This step, mediated by the enzyme pyruvate kinase (PK), is 
regulated by the cell’s energy status and regulates the entry of carbon atoms from 
glycolysis into the TCA cycle4. 
Looking at the whole sequence of glycolytic reactions, two ATP and two NADH 
molecules are produced per glucose molecule6. 
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The glycolytic cascade does not require oxygen availability, while to oxidize 
pyruvate to carbon dioxide through oxidative phosphorylation (OxPhos), oxygen 
is absolutely necessary. Aerobic respiration requires pyruvate, the final product of 
glycolysis, to be imported inside the mitochondria and decarboxylated to acetyl-
CoA. Acetyl-CoA is then converted to citrate before entering in the Krebs cycle. 
The Krebs cycle, also known as TCA cycle, generates NADH and carbon dioxide 
by oxidating acetyl-CoA. Reducing equivalents in the form of NADH are then 
used by the electron transport chain, which creates a proton gradient across the 
inner membrane of the mitochondria. This gradient then supports the energy to 
generate ATP. The complete catabolism of one glucose molecule via OxPhos can 
produce, in theory, up to 38 ATP molecules4. 
Under anaerobic or hypoxic conditions, pyruvate is transformed into lactate 
through lactic acid fermentation to keep glycolysis going, and thus to provide a 
source of ATP in the absence of efficient mitochondrial respiration. This reaction 
represents the final step of anaerobic glucose catabolism and it can be observed in 
skeletal muscles during intense activity, when tissue oxygen concentration is low. 
Lactate dehydrogenase (LDH) enzyme catalyses the conversion between pyruvate 
and lactate, regenerating NAD+ in the same reaction. Glycolysis requires NAD+ 
for the conversion of G3P in 1,3BPG, thus LDH has an important role in 
maintaining the cellular redox state to support the glycolytic cascade7. 
 
CONTROL	  OF	  GLYCOLYSIS	  	  
The glycolytic pathway is subjected to several regulatory mechanisms, based both 
on the availability of specific substrates and on the regulation of key enzymes. 
Among the ten enzymatic steps of glycolysis, three reactions are essentially 
irreversible, because of a free energy change that is largely negative. These three 
steps are: (1) glucose phosphorylation, catalyzed by hexokinases 1 and 2; (2) 
conversion of F6P in F1,6BP, carried out by PFK1; (3) transfer of phosphate from 
PEP to ADP, which generates ATP and pyruvate, by pyruvate kinase4. During 
gluconeogenesis, the reverse metabolic pathway that regenerates glucose from 
glycolytic intermediates, most steps are mediated by the same enzymes active 
during glycolysis, with the except ion of these three reactions. In these cases, 
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specific enzymes are activated and mediate the reverse reactions. HK, PFK1 and 
PK, which mediate the three irreversible and committing steps, are also the main 
regulatory sites of glycolysis and, among them, PFK1 is critical for the 
commitment of glucose to the glycolytic pathway5. 
Modulation of PFK1 activity is important to regulate glycolytic levels according 
to the cell’s needs. PFK1 is directly regulated by the energetic status of the cell, 
since ATP and AMP can inhibit or activate PFK1, respectively. Furthermore, 
high-energy metabolic intermediates, such as citrate and PEP, that accumulate in 
conditions of sufficient energy storage, also reduce PFK1 enzymatic function. 
Another end-product of glycolysis, lactate, can reduce PFK1 activity providing a 
negative feedback for the glycolytic cascade. This is one reason why cells relying 
on glycolysis as the main source for energy production secrete lactate, to keep 
glycolysis active8. 
The most potent positive regulator of PFK1 is fructose-2,6-bisphosphate 
(F2,6BP), which acts with an allosteric mechanism to increase the affinity of 
PFK1 for its substrate F6P. F2,6BP is able to bypass the inhibitory effect of ATP 
and act synergistically with AMP. F2,6BP is produced from F6P, such that F6P 
availability itself can foster PFK1 activity; F2,6BP is produced by a family of 
enzymes, the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB) 
family, that can mediate both the production (acting as kinases) or consumption 
(acting as phosphatases) of F2,6BP. The kinase (PFK2) and phosphatase (FBPase) 
functions of PFKFBs are encoded within the same protein, and the ratio between 
the two activities determines the amount of F2,6BP in the cell. In mammals, four 
genes (PFKFB1-4) encode for four different enzymes and, among these, PFKFB3 
is the one displaying the most active kinase function. Therefore, PFKFB3 
overexpression results in F2,6BP production and, in turn, on glycolysis 
stimulation. The kinase portion PFK2 can be regulated by hormonal stimuli: 
insulin and adrenalin signals enhance PFK2 functions, increasing glycolysis. 
Finally, the levels of F2,6BP are adjusted during the cell-cycle through an E3 
ubiquitin ligase5,8. 
 
	   	  
	   13	  
NUTRIENT-­‐SENSING	  MECHANISMS	  
 
Nutrient sensing is the ability of a cell to sense and respond to changes in essential 
metabolic substrates. In the presence of abundant nutrients, these signaling 
systems usually drive anabolic pathways (i.e. de novo synthesis of 
macromolecules) to permit cell duplication and/or storage pathways (such as 
glycogen or fatty-acid synthesis) to conserve resources. Otherwise, lack of 
nutrients triggers the rapid mobilization of internal stores through catabolic 
mechanisms such as glycogen break-down, fatty acid oxidation and, in extreme or 
prolonged starving conditions, autophagy. Cells detect their nutrient status both 
by directly measuring essential nutrients such as glucose, aminoacids and lipids, 
and by indirectly sensing the overall energy levels, i.e. the ratio between ATP and 
ADP (or AMP)6,9. 
Usually, nutrient sensing mechanisms act at two levels: the first is a feedback 
system that aims at maintaining homeostatic levels of a given molecule, by 
coordinating its uptake, storage and breakdown. This system typically acts by 
regulating the activity of key metabolic enzymes and their transcriptional levels, 
to provide short- and long-term adaptation. The second acts more indirectly, by 
coordinating the presence or absence of nutrients with other cellular processes, 
including other metabolic pathways and cell proliferation9. Glucose metabolism 
can influence gene transcription by two main mechanisms, mediating a form of 
metabolic adaptation to changing glucose levels. In one case, glucose (in its 
intracellular form of G6P) can directly regulate the subcellular localization of 
MondoA/ChREBP (carbohydrate-response element-binding protein) transcription 
factors as a feedback mechanism. Indeed these factors, acting together with their 
partner Mlx (Max-like protein x), mainly control the expression of enzymes 
involved in glycolysis and lipogenesis10,11. In the second case, glucose 
metabolism contributes to the overall levels of ATP, and this in turn regulates the 
activity of AMPK (AMP-activated protein kinase). When cells experience a 
condition of energy stress (i.e. low levels of ATP availability), AMPK 
phosphorylates TSC2 (tuberous sclerosis complex 2), promoting the inhibitory 
activity of TSC1–TSC2 towards the mTOR (mammalian target of rapamycin) 
complex. By this mechanism, AMPK inhibits anabolic processes and promotes 
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the activation of alternative catabolic pathways, such as autophagy, to re-establish 
ATP levels, thus maintaining energy homeostasis12. 
 
METABOLIC	  REPROGRAMMING	  OF	  CANCER	  CELLS:	  THE	  
WARBURG	  EFFECT	  
 
One central difference between normal tissues and cancer cells is the ability of the 
latter to proliferate without control. Cancer cells display a number of distinctive 
traits that allow them to proliferate in an uncontrolled way13; among these, a 
prominent one is an altered cell metabolism, centered on a higher rate of energetic 
and anabolic pathways4. 
In the presence of oxygen, most healthy cells metabolize glucose though oxidative 
phosphorylation to generate ATP. In the 1920s, the Nobel Prize Otto Warburg 
observed that cancer cells instead incorporate abnormally high levels of glucose 
and display a high rate of the lactate production, even in the presence of oxygen14. 
This phenomenon, known as “Warburg effect”, is observed because cancer cells 
generate lactate as principal end-product of glycolysis even if oxygen is available, 
thus performing “aerobic glycolysis”. Cancer cells rely on aerobic glycolysis even 
if this process is far less efficient than mitochondrial respiration in terms of ATP 
production (18-fold less), counterbalancing the low ATP yield with very high 
rates of glucose uptake7,15. This observation is still exploited clinically to detect 
tumors by positron emission tomography using 18F-fluorodeoxyglucose (FDG-
PET), an analog of glucose that enters into cells but cannot be metabolized15. 
Initially the energetic disadvantage of aerobic glycolysis seemed paradoxical. 
However, it later became clear that the functional advantage of this particular 
metabolism lays on the diversion of glucose-derived intermediates toward several 
biosynthetic pathways, which are fundamental to sustain the production of new 
daughter cells. Glycolysis intermediates can indeed provide carbon atoms for the 
synthesis of nucleotides, aminoacids and lipid precursors, all essential molecules 
to build new daughter cells. Aerobic glycolysis thus represents a metabolism 
particularly suited for cell growth and sustained proliferation4. Supporting this 
view, aerobic glycolysis is also naturally observed in non-transformed rapidly 
dividing cells, such as embryonic tissues and stem cell compartments6,16. 
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Furthermore, when placed in vitro in the presence of unlimited nutrients (glucose 
and glutamine), almost any cell type shifts its metabolism from oxidative 
phosphorylation to aerobic glycolysis, in the so-called Crabtree effect, suggesting 
this is the preferred metabolism in the presence of nutrients17.  
Aerobic glycolysis is characterized not only by high rates of glycolytic reactions, 
but also by the unusual production of lactate. Lactate generation maintains low 
levels of pyruvate, which otherwise inhibits glycolysis, and has an important role 
in maintaining the redox balance: pyruvate to lactate conversion regenerates 
NAD+, necessary to sustain the conversion of G3P in 1,3BPG during glycolysis. 
Moreover, NAD+ is essential for nucleotide and aminoacid biosynthesis and many 
other cellular functions4. Lactate freely diffuses from cells into interstitial fluids 
and blood; recently, it has been proposed that lactate secretion by tumor cells 
performing aerobic glycolysis can favor tumor invasiveness properties by acting 
on the microenvironment. For example, lactate stimulates VEGF production by 
endothelial cells, thus promoting angiogenesis and sustaining migration. Lactate 
can also act as a mediator of inflammatory reactions, favoring the production of 
pro-inflammatory cytokines by T-cells and macrophages. Moreover, tumor cells 
from the more oxygenated regions of a solid tumor can use lactate, produced in 
more hypoxic regions, as a fuel for oxidative phosphorylation. In turn, this sets 
glucose free for hypoxic tumor cells15,18. 
 
MOLECULAR	  MECHANISMS	  OF	  METABOLIC	  
REPROGRAMMING	  IN	  CANCER	  
 
Uncontrolled cell proliferation observed in cancer cells requires that constitutive 
pro-proliferation signals (oncogene activation, tumor-suppressor mutation) are 
coupled with an adaptation of glucose metabolism to fuel cell growth. In cancer 
cells, the metabolic switch from mitochondrial respiration to aerobic glycolysis is 
commonly observed upon activation of oncogenes or mutations in tumor 
suppressors19. One example is the c-Myc oncogene, which directly regulates both 
cell-cycle genes, such as cyclin D, and genes involved in glucose metabolism (i.e. 
LDH and PK enzymes, glucose transporters). In addition, c-Myc induces 
addiction to glutamine by increasing the expression of glutamine transporters and 
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glutamine catabolic enzymes. Glutamine is a fundamental nutrient that can be 
converted into other aminoacids, TCA intermediates (and thus, energy), or it can 
be a source of carbons, for fatty acids, and of nitrogen, for nucleotides. Thus, in 
transformed cells c-Myc generally promotes macromolecule synthesis and energy 
production required for sustained cell proliferation20. 
Rapid growth of solid tumors can cause cells to experience local low oxygen 
conditions which trigger adaptive responses to hypoxic environments, mediated 
by the HIF transcription factors (HIF1 and HIF2). Under normoxia, the α subunit 
of the HIF1 transcription factor is degraded, while limiting oxygen concentration 
induces α subunit stabilization and, in turn, activation of target gene transcription. 
HIF1 activation on one hand induces the expression of genes promoting formation 
of new blood vessels, such as VEGF, and in parallel adjusts cell metabolism to 
low oxygen conditions. Indeed, among the genes regulated by HIF, there are 
glucose transporters, all the main glycolytic enzymes (i.e. HK, PFK1, PK) and the 
pyruvate dehydrogenase kinase 1 (PDK1) enzyme, which skews pyruvate from 
oxidation to lactic fermentation. In this way, hypoxic cells reprogram their 
metabolism toward glycolysis (in this case, anaerobic glycolysis) in order to 
sustain energy production and cell proliferation21. 
The reprogramming of cell metabolism can occur also as a consequence of 
mutation in tumor suppressor genes. One of the most famous examples is the 
tumor suppressor p53. p53 controls the expression of genes related with glucose 
metabolism and acts by restraining glucose utilization. p53 positively regulates 
the expression of TIGAR, a FBPase that inhibits PFK1 activity and redirects 
glucose toward the PPP. As a consequence, mutations of p53 increase aerobic 
glycolysis5,22. In other cases, metabolic enzymes themselves display tumor 
suppressor functions, as observed for isocitrate dehydrogenase (IDH), fumarate 
hydratase (FH) or succinate dehydrogenase (SDH), key enzymes of the TCA 
cycle, which are often found inactivated/mutated in paraganglioma or 
leiomyosarcoma, respectively. Interruption of the TCA cycle and accumulation of 
intermediate metabolites precipitates these tumors in a para-hypoxic condition, 
leading to enhanced glycolytic levels23,24. 
Given its central role for glycolysis, it is perhaps not suprising that, among the 
glycolytic enzymes, PFK1 is often found expressed at high levels in cancer cells, 
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and cells displaying higher expression of PFK1 are the more aggressive ones, at 
least in some tumor types25,26. Moreover, also PFK2 enzymes, and in particular 
PFKFB3, are found elevated in human cancers or activated through post-
translational modifications and reduced degradation5. Collectively, this indicates 
that glycolysis is a central metabolic pathway, which is required for cancer cell 
proliferation and tumor progression. 	  
YAP/TAZ	  TRANSCRIPTIONAL	  CO-­‐ACTIVATORS 	  
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding 
motif (TAZ, also known as WWTR1) are two orthologous mammalian 
transcriptional coactivators that shuttle between the cytoplasm and the nucleus to 
regulate gene transcription. In the nucleus, they act mainly in combination with 
the TEAD/TEF family of DNA-binding transcription factors (TEAD1/2/3/4)27. 
The TEAD family is widely expressed in embryonic and adult tissues, providing a 
wide potential for YAP/TAZ responsiveness28. 
YAP/TAZ:	  sensors	  of	  multiple	  inputs	  
 
YAP/TAZ were discovered as downstream transducers of the Hippo pathway, an 
evolutionary conserved tumor suppressor signaling cascade that plays important 
roles in the control of tissue and organ size. The Hippo pathway was revealed 
through genetic screens in Drosophila; this identified a number of downstream 
effectors that are highly conserved in mammals. Genetic alterations in 
components of this signaling cascade lead to aberrant organ overgrowth, due to 
increased cell proliferation and decreased apoptosis28. In its basic formulation, the 
mammalian pathway operates as follows: MST1/2 (Macrophage Stimulating 1/2) 
kinases, in association with the regulatory subunit WW45-SAV (Salvador), 
phosphorylate and activate the LATS1/2 (Large Tumor Suppressor) kinases, 
which associate with their cofactors MOB1A/B (Mps One Binder 1A/B). MST1/2 
and LATS1/2 are homologous to Hpo and Wts Drosophila kinases, 
respectively28,29. Activated LATS1/2, helped by MOB1A/B factors, phosphorylate 
YAP and TAZ at multiple residues (S61, S109, S127, S164, S381 for human 
YAP, and S66, S89, S117, S311 for human TAZ). LATS1/2-mediated 
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phosphorylation inhibits YAP/TAZ activity through at least two different 
mechanisms: ubiquitination-dependent degradation and binding to 14-3-3 
proteins28,30. Several upstream regulators of the Hippo pathway have been 
identified, including NF2/Merlin, an important inhibitor of YAP/TAZ. In recent 
years, however, several variations on this basic signaling module have been 
reported, including LATS-independent phosphorylation of YAP/TAZ, MST-
independent activation of LATS, and phosphorylation-independent modalities of 
YAP/TAZ control31.  
A surge of publications in the last decade identified YAP/TAZ as downstream 
effectors of several inputs, including apico-basal cell polarity, epithelial-to-
mesenchymal transition (EMT), Wnt and other growth factor signaling cascades. 
Moreover, one of the most fascinating aspects of YAP and TAZ biology was the 
discovery that YAP/TAZ act as nuclear transducers of mechanical inputs such as 
extracellular matrix (ECM) stiffness, cell shape and cytoskeletal tension31,32. 
Thus, structural elements that originate at the tissue level, such as adhesion of a 
cell to its surrounding ECM, cell-cell junctions and the tensional forces of the 
cytoskeleton that keep cells, tissues and organs in a certain shape33, by acting on 
YAP/TAZ activity, can inform individual cells about properties of the tissue in 
which they are embedded. 
Recently, YAP/TAZ activity was also connected to the cell metabolism by the 
identification of the mevalonate pathway as a required input for YAP/TAZ 
activity in vitro. Mevalonate metabolism is indeed required for RHO membrane 
localization and activity, which in turn is required and sufficient for YAP/TAZ 
activity in a LATS-independent manner34. 
Thus, the emerging picture is that YAP/TAZ act as integrators of a series of 
converging cellular and tissue-embedded cues to determine cell behaviour in a 
coherent and coordinated manner. 
YAP/TAZ	  functions	  in	  normal	  tissues	  
 
YAP/TAZ factors can regulate cell proliferation in many tissues and organs. This 
is underscored by the seminal observation that knockout of Hippo genes or 
activation of YAP in mammalian tissues (such as liver, heart and skin) cause 
tissue hyperplasia and organ overgrowth. Conversely, genetic deletion of YAP 
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from several fetal tissues results in impaired cell proliferation. During 
development, full YAP knockout results in embryonic lethality, further worsened 
by the combined YAP and TAZ knockout28,29,35. These observations, together 
with the finding that YAP/TAZ are broadly required for proliferation of cells in 
vitro, led to the idea that YAP/TAZ are general required factors for cell 
proliferation29,36,37. This idea was however recently challenged by the finding that 
in mouse some adult tissues, including the intestine, can survive in the absence of 
YAP and TAZ38,39. Thus, it is possible that YAP/TAZ are key for proliferation 
upon tissue damage, during regeneration or during tumor progression, but not in 
normal physiological conditions, at least in the adult. 
YAP/TAZ	  activity	  is	  increased	  in	  cancer	  cells	  and	  required	  for	  tumor	  
development	  	  
All available data point to a powerful tumor-promoting activity of YAP/TAZ. In 
line with a tumorigenic role, YAP and TAZ are found overexpressed or amplified 
in several human cancers, such as lung, pancreas, liver, oral squamous-cell 
carcinomas and breast cancer. Experimentally, overexpression of YAP is 
sufficient to induce cell hyperplasia and tumorigenesis, either alone or in 
combination with other oncogenes28,29,35. Finally, recent data indicate that 
YAP/TAZ are strongly required for experimental tumorigenesis in the intestinal 
epithelium and in the skin, and that YAP expression can substitute one of the most 
powerful oncogenes, Ras, in sustaining pancreas cancer development40. These 
findings, together with the observation that YAP/TAZ are not required in at least 
some adult normal tissues, indicate that inhibiting YAP/TAZ activity might be an 
ideal target to harm cancer cells. Moreover, a common theme in many of recent 
studies is that much of the functions of YAP/TAZ are mediated by TEADs, such 
that disruption of the YAP/TAZ-TEAD protein–protein complex is considered an 
important way to disable YAP/TAZ activity41,42.  
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Rationale	  	  
 
The reprogramming of cell metabolism toward aerobic glycolysis is a hallmark of 
cancer, indicating that aerobic glycolysis provides a selective advantage that 
favors cancer cell growth. According to current views, metabolic reprogramming 
is considered as a simple phenotypic endpoint that occurs as a consequence of 
oncogene activation and tumor formation. Increasing evidence however indicates 
that metabolic pathways also incorporate signaling mechanisms that inform and 
coordinate other cellular functions, including nuclear gene transcription and 
epigenetics. In this manner, metabolic pathways can even play causative roles in 
regulating cell behavior, in addition to their core biochemical functions7,12,19,43.  
Our study explored the possible links between glucose metabolism and gene 
transcription, starting from the hypothesis that known transcriptional pathways, 
relevant for cancer cell proliferation and aggressiveness, might “sense” aerobic 
glycolysis. In this way, metabolism and gene transcription should be coordinated 
to promote cancer cell proliferation. We started our analysis by performing a 
genome-wide microarray profiling to obtain a list of genes regulated by glucose. 
Bioinformatic analyses showed that YAP/TAZ target genes are positively 
regulated by glucose metabolism. We then validated that inhibition of glucose 
metabolism hampers YAP/TAZ-induced in vitro tumorigenic phenotypes in breast 
cancer cells, including proliferation, clonogenic activity and promotion of self-
renewal properties. This regulative axis is strikingly conserved in Drosophila, 
where inhibiting glycolysis blunts tumorigenic clonal expansion induced by 
Yorkie, the homologue of YAP/TAZ. Finally, and in keeping with the idea of 
oncogenic signaling at the service of a metabolic pathway, growth/survival 
promoted by glucose require YAP/TAZ activity in human cancer cells. 	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Results	  	  	  
GLUCOSE	  METABOLISM	  REGULATES	  YAP/TAZ	  ACTIVITY	  	  
To analyze the link between glucose metabolism and gene transcription, we asked 
whether glucose metabolism could regulate known signaling pathways relevant 
for embryonic development, adult tissue homeostasis and disease. For this, we 
performed a genome-wide microarray expression profiling and compared cells 
growing in high glucose (which favors aerobic glycolysis due to the Crabtree 
effect) with cells treated for 24h with 2-deoxy-glucose (2DG, 50mM), a widely 
used competitive inhibitor of glucose metabolism acting at the level of 
hexokinase44. In this way we obtained a list of genes regulated by glucose 
metabolism. The underlying idea is that, if glucose regulates the activity of a 
transcription factor, the target genes of this factor will be regulated by glucose. 
The dose of 2DG used in this experiment is commonly used in cell cultures to 
block glucose metabolism and was sufficient to inhibit aerobic glycolysis and to 
increase mitochondrial respiration in our cells, as measured with an extracellular 
flux analyzer (see below), and to inhibit cell growth. 
We then performed a gene set enrichment analysis (GSEA), searching for more-
than-random correlations between the genes regulated by 2DG (either up- or 
down-regulated) and those contained in a collection of gene signatures denoting 
activation of transcription factors and signaling pathways. Since most of these 
signatures were derived from mammary cell lines, we performed the experiments 
in MDA-MB-231 breast cancer cells and MCF10A mammary epithelial cells. 
Several signatures appeared regulated, either up or down, upon 2DG treatment, in 
line with the profound effects of glucose on cell behavior. For instance, genes 
regulated by Notch or TGFβ were enriched upon inhibition of glucose 
metabolism, while E2F and Myc target genes were positive correlated with 
glucose. Among others, the signature indicating activation of YAP/TAZ was the 
most significantly overrepresented within the genes inhibited by 2DG treatment in 
both cell lines, whereas the genes repressed by YAP were enriched among the 
genes activated by 2DG (Fig. 1A) This was also confirmed by monitoring the 
	  22	  
overall levels of the YAP/TAZ signatures in our microarrays, which was 
consistently downregulated upon inhibition of glucose metabolism (Fig. 1B). Of 
note, basal levels of YAP/TAZ target genes were higher in the cell line displaying 
higher glycolysis/respiration ratio, i.e. in MDA-MB-231 cells (Fig. 1C). 
Our GSEA analysis suggested a link between glucose and YAP/ TAZ, but did not 
inform us about what is upstream and what is downstream. We initially 
investigated whether YAP/TAZ regulate glucose metabolism by monitoring 
aerobic glycolysis and mitochondrial respiration levels in mammary epithelial 
cells expressing activated TAZ. Even if TAZ activation is per se sufficient to 
endow these cells aggressive traits in vitro and in vivo45, we did not observe 
notable changes in glycolysis or respiration (Fig. 1D). Moreover, by surveying 
microarrays obtained by activation or inhibition of YAP/TAZ in multiple cellular 
systems27,46,47, we failed to observe consistent regulation of glucose transporters 
or glycolytic genes that are instead typically induced by oncogenes15,20. Thus, 
YAP/TAZ are not obvious inducers of aerobic glycolysis. 
In order to validate our bioinformatics analysis, we then tested whether glucose 
metabolism regulates YAP/TAZ. For this, we treated MDA-MB-231 cells, 
displaying high basal YAP/TAZ activation, with 2DG or Lonidamine (another 
widely used inhibitor of hexokinase44) for 24h. To directly monitor YAP/TAZ 
transcriptional activity, we transfected cells with the luciferase reporter 8XGTIIC-
lux, based on TEAD-responsive elements and whose dependence on YAP/TAZ 
has been previously checked (31 and Fig. 2A). As shown in Fig. 2A, these 
treatments inhibited YAP/TAZ activity, whereas treatment with OligomycinA, an 
inhibitor of mitochondrial respiratory chain, did not inhibit YAP/TAZ activity. 
This confirmed our initial findings, but also suggested a regulation not generically 
linked to energy metabolism. In line with a specific inhibition, the effect of 2DG 
was reversible (Fig. 2A) and was not caused by general inhibition of glycosylation 
(Fig. 2B); this was tested because 2DG could in principle compete for mannose 
and interfere with N-linked glycosylation48. Similar results were obtained with the 
CTGF-lux reporter (Fig. 2C), based on the natural human CTGF promoter, a well 
established YAP/TAZ target27,29,49. Moreover, we observed similar results in the 
highly glycolytic Hs578T breast cancer cells (Fig. 2D) and in the HepG2 
hepatocellular carcinoma cells (Fig. 2E), indicating a mechanism conserved in 
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different cell lines. Finally, a reporter for the Notch pathway and a reporter driven 
by the CMV promoter were not inhibited, ruling out generic effects of 2DG 
treatment on gene transcription (Fig. 2F and 2G). Collectively, these data 
confirmed that inhibition of glucose metabolism inhibits YAP/TAZ activity. 	  
Glucose inhibition induces a fast adaptation of cellular metabolism and then 
secondarily induces other cellular responses, including growth arrest; thus, among 
the genes regulated by glucose, some could be regulated as a direct consequence 
of glucose inhibition, while others may be indirect targets of growth arrest. An 
example of the second class are the E2F-regulated genes50,51 that were highly 
enriched in our GSEA analysis (Fig. 1A, E2F3 signature); indeed, we found by 
luciferase assays that E2F activity is inhibited by 2DG and also by inducing 
growth arrest through expression of established CDK inhibitors (p21/CDKN1A, 
p16/CDKN2A, p27/CDKN1B) (Fig. 3A top). In contrast, CDK inhibitors do not 
inhibit YAP/TAZ activity (Fig. 3A bottom). Thus, growth arrest and/or E2F 
inhibition is not sufficient to explain YAP/TAZ inhibition by 2DG.  
To test the idea of a direct/proximal effect of glucose metabolism on YAP and 
TAZ activity, we developed a doxycycline-inducible version of the 8XGTIIC-lux 
reporter, stably integrated in our cells, allowing us to visualize YAP/TAZ 
responses in a restricted time-window. Cells were supplemented with doxycycline 
for 4, 6, 8 or 10h to release YAP/TAZ-dependent transcription, and compared 
with cells treated also with 2DG. As shown in Fig. 3B, 2DG treatment inhibited 
YAP/TAZ at the earliest time points, indicating a rapid response. Importantly, we 
observed a reduced YAP/TAZ activity also in cells cultured in absence of glucose 
(Fig. 3C). Similar results were obtained in HepG2 (Fig. 3D) and in MCF10A-MII 
cells (Fig. 3E-G). This observation is thus compatible with a direct regulation of 
YAP/TAZ activity. 	  
To validate further the link between glucose and YAP/TAZ, we checked whether 
endogenous target genes inhibited by 2DG were coherently regulated also upon 
knockdown of YAP/TAZ. To select candidate co-regulated genes, we compared 
microarray profiling of genes regulated by 2DG with microarrays of cells depleted 
of YAP/TAZ by two independent couples of siRNAs, previously carried out in 
our laboratory in the same cellular lines (MDA-MB-231 and MCF10A). Out of 
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this analysis, we could identify several probes that were similarly co-regulated 
(either up or down) by glucose and by YAP/TAZ in both cell lines. Among the 
strongest co-regulated microarray probes in MDA-MB-231 cells, we successfully 
validated a series of transcriptional targets by qPCR, concordantly repressed or 
activated by 2DG and YAP/TAZ knockdown, including the established 
YAP/TAZ targets HMMR, TK1 and RRM252,53 (Fig. 4A). Noteworthy, the same 
target genes were also regulated by 2DG treatment and YAP/TAZ knockdown in 
another breast cancer cell line, Hs578T (Fig. 4B). This indicates that a portion of 
the genes regulated by 2DG is also regulated by endogenous YAP/TAZ. Other 
YAP/TAZ targets, such as CTGF or ANKRD1, were not regulated, likely due to 
compensating parallel inputs. Interestingly, Gene Ontology analysis indicates that 
the genes co-regulated by glucose and YAP/TAZ are particularly related to cell 
cycle control and to DNA synthesis, repair and metabolism (Fig. 4C), in keeping 
with the validation of TK1, TYMS, RRM2 (required for nucleotide biosynthesis) 
and CDC (Cell Division Cycle) factors shown above. 
Collectively, these results indicate that YAP/TAZ transcriptional activity is 
sustained by glucose metabolism. 
 
YAP/TAZ	  ACTIVITY	  IS	  REGULATED	  BY	  GLYCOLYSIS	  
 
We then asked which metabolic pathway fueled by glucose was mainly 
responsible for YAP/TAZ regulation. Once entrapped in the cell in the form of 
G6P, glucose can redirect into various metabolic pathways, such as PPP, 
glycolysis and HBP. Both glycolysis and HBP require the conversion of G6P into 
F6P by the enzyme GPI (Fig. 5A). To test if GPI was involved in YAP/TAZ 
regulation, we depleted cells of endogenous GPI with two independent siRNAs, 
and found this was sufficient to recapitulate the effects of 2DG treatment (Fig. 
5B-C). This result excluded the PPP as the main regulator of YAP/TAZ 
downstream of glucose. 
Downstream of GPI, F6P can be used either by PFK1 in the glycolytic cascade or 
by glucosamine-fructose-6-phosphate transaminase (GFPT), the first enzyme of 
HBP. To test a potential involvement of the HBP, we used two strategies: first, we 
blocked the activity of GFPT by treating cells with 6-diazo-5-oxo-L-norleucine 
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(DON) or O-diazoacetyl-L-serine (AZS) for 24h, at doses commonly used in 
cancer cells26,54,55. Second, we tested if the major pathway fed by the HBP, i.e. 
protein glycosylation, was involved in the regulation of YAP/TAZ; for this we 
supplemented N-Acetyl Glucosamine (GlcNAc) in the culture medium, which is 
sufficient to reactivate glycosylation in absence of glucose54,55. However, neither 
DON or AZS treatments inhibited YAP/TAZ activity (Fig. 5D), nor GlcNAc 
rescued YAP/TAZ inhibition by 2DG (Fig. 5E). Altogether, this made unlikely 
that the HBP and protein glycosylation are major regulators of YAP/TAZ; this 
also suggested glycolysis as the key metabolic pathway regulating YAP/TAZ.  
To verify this hypothesis, we then sought to modulate glycolytic levels and see 
whether this was sufficient to modulate YAP/TAZ activity. For this, we cultured 
cells for one week in the presence of galactose instead of glucose: in this 
condition aerobic glycolysis is less favorable and cells shift their metabolism 
toward oxidative phosphorylation to sustain efficient ATP production17,56–58. We 
first checked glycolysis levels in cells cultured in galactose by measuring 
extracellular acidification rate (ECAR – an indirect measure of lactate production, 
and thus of aerobic glycolysis) and oxygen consumption rate (OCR – a direct 
measure of mitochondrial respiration). As expected, we observed a strong 
decrease in ECAR and a substantial increase in OCR, confirming the metabolic 
shift from aerobic glycolysis to oxidative phosphorylation in cells cultured in 
galactose (Fig. 6A-D). We then measured YAP/TAZ activity in these different 
cell populations, by using the stably integrated YAP/TAZ luciferase reporter 
system described above. Strikingly, cells with reduced glycolysis displayed a 
corresponding reduction of YAP/TAZ activity; moreover, adding back glucose to 
galactose-fed cells during the last hours of the experiment was sufficient to rescue 
YAP/TAZ activity (Fig. 6E-F), in line with a rapid response of YAP/TAZ to 
glucose shown before.  
To further test the connection between glycolysis and YAP/TAZ we used 
UOK262 kidney cancer cells, which are highly glycolytic because of a mutation 
of the fumarate hydratase (FH) enzyme of the TCA cycle, and their FH-
reconstituted counterpart, which have reduced glycolysis as they restore 
mitochondrial respiration59,60. By luciferase assay we found a downregulation of 
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YAP/TAZ activity in UOK262 upon reconstitution of the FH enzyme (Fig. 6G), 
in line with our hypothesis. 
These results collectively support the notion that glycolysis plays a key role in the 
regulation of YAP/TAZ by glucose metabolism. 
 
EXPLORING	  THE	  MECHANISMS	  OF	  YAP/TAZ	  REGULATION	  
 
To understand how glycolysis could regulate YAP/TAZ we initially tested the 
involvement of known YAP/TAZ regulators, such as the Hippo kinase 
cascade28,61, the mevalonate pathway34,52, or key molecules involved in nutrient-
sensing pathways, such as AMPK and mTOR12,62. 
YAP/TAZ	  regulation	  by	  glucose	  metabolism	  is	  independent	  on	  
Hippo	  signaling	  and	  mevalonate	  	  
The best-known regulation of YAP/TAZ occurs by inhibitory phosphorylation 
from the LATS1/2 kinases, downstream of the Hippo pathway. We thus reasoned 
that glucose metabolism could keep LATS1/2 inhibited, in turn promoting 
YAP/TAZ activity. To directly test this hypothesis we depleted LATS1/2 kinases 
with two independent sets of siRNAs32,34 in MDA-MB-231 cells. As shown in  
Fig. 7A LATS1/2 knockdown was able to completely rescue the inhibition 
induced by NF2 reconstitution31, but was not sufficient to rescue the inhibition by 
2DG treatment, ruling out an involvement of the Hippo cascade. 
We then checked if 2DG treatment could regulate YAP/TAZ acting on 
mevalonate metabolism. In principle, glycolysis can regulate Acetyl-CoA, which 
is a precursor of mevalonate metabolism; mevalonate in turn is known to be 
required for Rho geranylgeranylation, and this is relevant to regulate YAP/TAZ 
activity34. We challenged this pathway by providing cells with non-limiting 
amounts of mevalonate, but found this was not sufficient to rescue 2DG inhibition 
(Fig. 7B). As a positive control, mevalonate rescued inhibition caused by 
Cerivastatin treatment, a small-molecule inhibitor of Acetyl-CoA to mevalonate 
conversion34. In line, 2DG induced a very minor nuclear exclusion when 
compared to Cerivastatin treatment (Fig. 7C). 
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YAP/TAZ	  regulation	  by	  glucose	  metabolism	  is	  independent	  on	  
AMPK/mTOR	  
 
To test if AMPK/mTOR nutrient-sensing signaling is involved in the regulation of 
YAP/TAZ by glucose metabolism, we used two approaches: first, we inhibited 
mTOR activity in MDA-MB-231 cells cultured in high glucose, a condition with 
low AMPK and high mTOR activity; second, we blocked AMPK activity upon 
2DG treatment, a condition where AMPK is activated. As shown in Fig. 7D-F, 
neither treatment with the dual mTORC1/2 inhibitor AZD201463,64 inhibited 
YAP/TAZ, nor blockade of AMPK activity with Compound C (a well-established 
inhibitor of AMPK) treatment or siRNAs transfection rescued them from 2DG. Of 
note, these treatments efficiently regulated dephosphorylation of the established 
AMPK/mTOR downstream target ribosomal protein S612,62 (Fig. 7D-E) and 
siRNAs efficiently depleted AMPK levels (Fig. 7F). 
PFK1	  interacts	  with	  TEADs	  	  
To gain insights into other possible mechanisms by which glycolysis regulates 
YAP/TAZ, we explored the YAP interactome. For this, we pulled-down a stably 
over-expressed form of YAP (FLAG-tagged YAP 5SA mutant) in MCF10A and 
MDA-MB-231 cells and identified coprecipitating proteins by mass-spectrometry 
(MS). As shown in Fig. 8A, we isolated several known interactors of YAP, 
including established cytoplasmic and nuclear complexes65–67. We then turned our 
attention to novel interacting proteins, with particular attention to enzymes 
involved in glucose metabolism; indeed it has been previously shown that some 
metabolic enzymes, such as PKM2 for example, can fulfill non-metabolic 
functions by interacting with transcription factors43,68. Among new potential 
YAP-binding proteins, our attention was immediately retained by the isolation, in 
both cell lines, of the phosphofructokinase enzyme isoform P (PFK1). This 
suggested the very interesting possibility that YAP/TAZ might crosstalk with 
PFK1, and thus with glycolysis. 
PFK1 mediates the first committed step of glycolysis and it is a central enzyme 
for the regulation of glycolysis. Recent reports indicate that cancer cells take 
control over glycolysis by multiple mechanisms acting, directly or indirectly, on 
PFK1 activity4,5,69. Moreover, PFK1 and PFK2 (i.e. the enzyme feeding F2,6P to 
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PFK1) expression is elevated in advanced breast tumors25,26, making PFK1 an 
interesting candidate to link glucose metabolism and YAP/TAZ activity. To 
explore the functional relevance of this biochemical observation, we designed two 
independent siRNA duplexes to target endogenous PFK1 expression (Fig. 8B), 
and challenged YAP/TAZ activity. Remarkably, knockdown of PFK1 caused 
inhibition of YAP/TAZ activity in MDA-MB-231 cells, as assayed by using 
8XGTIIC-lux and CTGF-lux reporters (Fig. 8C-D). Thus, PFK1 is required to 
sustain YAP/TAZ activity, and recapitulates the effects of 2DG shown above. 
 
So far, results indicate that PFK1 and glucose metabolism are required to sustain 
YAP/TAZ transcriptional functions. To dissect the molecular mechanism 
underlying this regulation, we sought to validate a direct interaction between YAP 
and PFK1, which was suggested by MS analysis. Co-immunoprecipitation 
experiments between recombinant FLAG-PFK1 and bacterially expressed YAP 
failed however to detect any direct binding (Fig. 9A). We then reasoned that co-
immunoprecipitation could reveal both direct and indirect YAP binding partners, 
as suggested by the isolation of NF2 from MCF10A, which indirectly binds to 
YAP70. Given that, our experiments pointed to a direct effect of glucose 
metabolism on YAP/TAZ transcriptional activity, we thus asked whether this 
regulation could act at the level of YAP/TAZ-TEADs transcriptional complexes. 
Surprisingly, as shown in Fig. 9B we could detect a direct binding between 
recombinant GST-TEAD4 and FLAG-PFK1. Moreover, we were able to detect a 
binding between PFK1 and TEADs both in lysates from cells expressing MYC-
TEAD4 and FLAG-PFK1 (Fig. 9C) and by immunoprecipitating endogenous 
TEAD1 with endogenous PFK1 (Fig. 9D). We also tested if the interaction of 
TEADs to PFK1 required the presence of YAP by using the mutated form of 
TEAD4 Y429H, unable to bind YAP71, but YAP seemed to be dispensable (Fig. 
9C). Finally, we performed immunostainings with two different anti-PFK1 
antibodies and found a proportion of the protein localized into the nucleus (Fig. 
9E), in line with the interaction with nuclear TEAD proteins. In addition, we 
revealed PFK1/TEAD1 complexes by using the proximity ligation assay (PLA), a 
technique enabling in situ quantitative detection of endogenous protein–protein 
complexes72, and detected PLA signals corresponding to endogenous 
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PFK1/TEAD1 complexes in the nucleus (Fig. 9F). 
We then explored whether PFK1 enzymatic activity was required for TEAD 
binding and YAP/TAZ activity. PFK1 activity is potently activated by its 
allosteric modulator F2,6BP5,73,74. F2,6BP levels are regulated by PFK2 enzymes 
and, among these, the PFKFB3 isoform preferentially promotes the 
phosphorylation of F6P to F2,6BP, thus stimulating PFK1 activity8,75,76. We thus 
tested if PFKFB3 could promote YAP/TAZ transcriptional activity. As shown in 
Fig. 9G, transfection of PFKFB3 dose dependently enhanced the activity of the 
YAP/TAZ/TEAD reporter in HEK293 cells, which typically display low levels of 
YAP/TAZ activity77. Conversely, mutation of five key aminoacid residues of 
PFK1, required for F2,6BP binding, reduced the binding with TEAD4 (Fig. 9H). 
Altogether, these results indicate that it is the enzymatically-active pool of PFK1 
that binds TEADs and fosters YAP/TAZ activity. 
 
GLUCOSE	  METABOLISM	  REGULATES	  THE	  INTERACTION	  
BETWEEN	  TEADS	  AND	  YAP/TAZ	  
 
Prompted by the finding of a PFK1-TEAD interaction, we next asked whether 
glucose metabolism regulates the formation of the YAP/TAZ-TEAD complex. 
Co-immunoprecipitation experiments of endogenous proteins revealed that YAP 
and TAZ interaction with TEAD1 decreased both upon 2DG treatment and 
glucose withdrawal (Fig. 10A-G), without leading to quantitative YAP or TEAD1 
nuclear exclusion (Fig. 10H and see Fig. 7C). In addition, providing glucose to 
glucose-starved cells restored the binding between YAP and TEAD1 (Fig. 10F-
G). Of note, we obtained similar results by using different antibodies to 
immunoprecipitate YAP or TAZ, and by repeating the experiment from extracts 
of MDA-MB231, MCF10A, HepG2 and UOK262 cells, indicating a general 
phenomenon. Finally, we sought to test the requirement of PFK1 for the binding 
between YAP and TEAD1, by using both co-immunoprecipitation experiments 
and PLA detection of endogenous YAP/TEAD protein-protein complexes. As 
shown in Fig. 10I-J, downregulation of PFK1 inhibited the binding between YAP 
and TEAD1.  
TEADs represent the DNA-binding platform for YAP/TAZ at gene promoters. 
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We thus selected some genes with known or predicted TEAD binding sites, such 
as HMMR, TK1, CTGF and ANKRD127,52,53 and we verified if the recruitment of 
YAP at these promoters was affected upon 2DG treatment. As shown in Fig. 11A-
B, chromatin immunoprecipitation (ChIP) analyses revealed that inhibition of 
glucose metabolism reduced the binding of YAP to the regulatory regions of its 
target genes, in line with inhibition of YAP/TAZ-TEAD complexes. Of note, this 
analysis was carried out based on known targets of YAP/TAZ, such as CTGF, 
ANKRD1 and RHAMM, and also on a novel target, TK1, included in the analysis 
because it is jointly regulated by glucose and YAP/TAZ (see Fig. 4A). By visual 
inspection we indeed identified two conserved TEAD-binding motifs in the 
proximal promoter region of the TK1 gene, which are sufficient to drive 
YAP/TAZ dependent transcription in luciferase assays (Fig. 11C) and respond to 
glucose metabolism (Fig. 11D). Collectively, our results suggest that glucose 
metabolism regulates the stability of YAP/TAZ-TEAD complexes at gene 
promoters. 
To further strengthen the finding that glucose metabolism regulates the ability of 
YAP/TAZ to interact with TEADs, we reasoned that a TEAD1 isoform (Y406A 
mutant) unable to bind YAP/TAZ78 should be insensitive to modulation of 
glucose metabolism. To test this, we took advantage of the UAS-GAL4 system to 
compare the activity of TEAD isoforms without interference from endogenous 
complexes; with this system it was possible to uncouple the basal transcriptional 
activity of TEAD1 (observed in the Y406A mutant) from YAP/TAZ-induced 
transcription (observed only with WT TEAD1). As shown in Fig. 11E, 2DG 
inhibited transcription driven by WT GAL4-TEAD1, but was unable to inhibit the 
basal activity of the Y406A GAL4-TEAD1 mutant in MDA-MB-231 cells. 
Moreover, overexpressing PFKFB3 in HEK293 selectively enhanced transcription 
driven by WT GAL4-TEAD1 (Fig. 11F). 
In sum, we thus propose a model in which PFK1 acts as a scaffold protein to 
promote YAP/TAZ-TEADs interaction and gene transcription. 
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INTERPLAY	  OF	  GLYCOLYSIS,	  PFK1	  AND	  YAP/TAZ	  FOR	  
CANCER	  CELL	  GROWTH	  	  
Data shown so far indicates that YAP/TAZ require glycolysis for full activation. 
So, we hypothesized that phenotypes induced by YAP/TAZ should be 
counteracted by inhibiting glucose metabolism. 
First we challenged the ability of activated S89A-mutant TAZ to promote self-
renewal of MCF10A-MII mammary cells in a previously established 
mammosphere-forming assay34,45. Inhibition of glycolysis by 2DG treatment, or 
by transfection of PFK1 and GPI siRNAs, potently blocked the effects of TAZ 
(Fig. 12A-D). 
Second, we challenged the ability of YAP to promote anchorage-independent 
growth in soft agar, another established hallmark of YAP activation79. 
Knockdown of PFK1 by siRNA transfection decreased the basal clonogenic 
potential of MDA-MB-231 cells, recapitulating the inhibition of YAP/TAZ (Fig. 
12E); moreover, blockade of glucose metabolism with 2DG inhibited the growth 
of colonies experimentally induced by expression of activated YAP-5SA (Fig. 
12F). 
Third, we took advantage of the fact that YAP/TAZ activity can be inhibited in 
mammary epithelial cells grown at high confluence, leading to growth arrest, and 
then locally reactivated by inducing a ‘‘wound’’ in the monolayer, enabling cell 
proliferation. This happens because cells close to the edge of the wound can 
stretch and remodel their F-actin cytoskeleton, leading to reactivation of 
YAP/TAZ32,80. As shown in Fig. 12G-H, cells close to the wound, but treated with 
2DG, re-entered cell proliferation much less efficiently than untreated cells, 
indicating that glucose metabolism is required to sustain YAP/TAZ-induced 
proliferation. 
 
To further extend the functional connections between glucose metabolism and 
YAP/TAZ we tested if proliferation promoted by glucose would depend, at least 
to some extent, on YAP/TAZ. In control MDA-MB-231 cells, 48h of nutrient 
deprivation (glucose and glutamine) induces growth arrest, and supplementing 
back glucose in the medium restarts proliferation (as measured by BrdU 
incorporation). Strikingly, upon YAP/TAZ silencing, glucose-induced 
	  32	  
proliferation is greatly impaired (Fig. 12I), although not completely as expected 
from the general (and YAP/TAZ independent) functions of glucose. 
We also compared parental UOK262 cells (glycolytic) with FH-reconstituted 
UOK262 cells (that rely more on mitochondrial respiration59,60) for their 
sensitivity to inhibition of glucose metabolism and of YAP/TAZ. As expected, in 
clonogenic assays parental UOK262 cells are more sensitive to 2DG (Fig. 12J). In 
line with our findings, parental cells relying on high levels of aerobic glycolysis 
were also more sensitive to inhibition of YAP/TAZ activity by verteporfin (VP), a 
small-molecule that specifically impairs the binding of YAP/TAZ to TEADs41 
(Fig. 12K). 
PFK1	  is	  required	  for	  YAP/TAZ-­‐dependent	  growth	  in	  vivo  	  
Having found that pro-tumorigenic phenotypes and proliferation induced by 
YAP/TAZ require glucose metabolism, we then asked whether this was relevant 
also in vivo. For this, we used the Drosophila model system, in collaboration with 
Prof. Grifoni (UniBo). Drosophila imaginal discs are well-established 
experimental systems for Yorkie (Yki) activity, the fly homolog of YAP/TAZ: 
Yki hyperactivation, in the context of a lethal giant larvae tumor-suppressor (lgl-) 
mutant background81–83, causes tissue overgrowth61,84. As shown in Fig. 13A, 
silencing of Pfk by RNAi inhibited the growth of Yki-overexpressing cells. 
Importantly, this was associated also in Drosophila with inhibition of Yki 
transcriptional activity, because we observed decreased expression of DIAP1 and 
dMyc, established Yki/TEAD target genes in Drosophila85–88, upon Pfk RNAi 
(Fig. 13B-E). This suggests that Pfk is instrumental for Yki activity during 
tumorigenic growth of fly larval tissues. 
 
Collectively, our findings indicate that glycolysis is required for the full 
deployment of YAP/TAZ tumorigenic activities, and that YAP/TAZ mediate a 
segment of the proliferative effects of glucose metabolism, reflecting regulation of 
YAP/TAZ transcription downstream of glucose in human cells and fly tissues. 
Mechanistically we found that glycolysis regulates YAP/TEAD complex 
formation, which is in line with the requirement of TEAD binding for most 
YAP/Yki tumorigenic activities, and in particular for the biological assays used 
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above27,47,86. 
CORRELATION	  BETWEEN	  HIGH	  YAP/TAZ	  ACTIVITY	  AND	  
HIGH	  LEVELS	  OF	  A	  GENE	  SIGNATURE	  ASSOCIATED	  TO	  
GLYCOLYSIS	  IN	  PRIMARY	  HUMAN	  BREAST	  CANCERS	  	  	  	  
YAP/TAZ activation and a shift toward a glycolytic metabolism are commonly 
observed during tumor progression. This is true in particular for breast cancers, 
where YAP/TAZ activity is associated with high-grade (G3) tumors and with the 
cancer-stem-cell (CSC) content of the tumors, reflecting YAP/TAZ requirement 
for CSC self-renewal and cancer aggressiveness45,89. Moreover, mammary tumor-
initiating cells and undifferentiated basal-like breast cancers display a shift toward 
aerobic glycolysis, which in turn is required for their self-renewal ability90,91. 
Given our results for a direct link between glycolysis and YAP/TAZ activity, we 
sought to test if YAP/TAZ activation specifically associates with glucose 
metabolism also in primary human mammary tumors. 
We first derived a gene expression signature experimentally associated with high 
glucose metabolism in cells of mammary origin (glucose signature) by selecting 
the genes that were downregulated by 2DG treatment both in MCF10A and 
MDA-MB-231 microarrays. We then analyzed a large metadataset collecting gene 
expression and associated clinical data of more than 3600 primary mammary 
tumors45,92, and evaluated how the levels of glucose signature were associated 
with YAP/TAZ activity. Strikingly, bioinformatic analyses showed that glucose 
signature is positively and strongly correlated with expression of previously 
established gene signatures denoting YAP/YAZ activity (Fig. 14A-B); moreover, 
tumors classified according to high (vs. low) glucose signature also display 
corresponding high and low activity of YAP/TAZ (Fig. 14C-D). 
Prompted by this observation, we tested whether the glucose signature correlates 
with cancer features previously associated to YAP/TAZ activity, such as tumor 
grade and the content of CSC45,89. As shown in Fig. 14E-G, we indeed found that 
glucose signature expression levels associated to higher expression of mammary 
stem cell signatures93,94, and it was significantly elevated in G3 vs. G1 grade 
tumors (p<0.0001). Remarkably, by univariate Kaplan-Meier survival analysis we 
also found that tumors expressing high levels of the glucose signature (“High”) 
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displayed a significant higher probability to develop recurrence when compared to 
the “Low” group (Fig. 14H). Of note, the higher expression of the glucose 
signature in G3 tumors, and its ability to stratify patients, was completely lost 
when we selected from the glucose signature only the genes that were regulated 
by 2DG but not by YAP/TAZ siRNA (Fig. 14I-J). Collectively, these data 
indicate that during mammary tumor progression metabolic reprogramming 
toward aerobic glycolysis is accompanied by elevated YAP/TAZ activity. 
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Discussion	  	  
 
Cell metabolism and signaling pathways are powerful regulators of cell 
proliferation and tumorigenesis. A coherent biological response integrates these 
separate inputs, linking cellular metabolism with pathways that sustain cell 
growth13,15. With this work we propose that glycolysis, besides its core 
biochemical role, also contributes to regulate the activity of YAP/TAZ; in so 
doing, glycolysis fuels the proliferative and tumorigenic functions of these 
powerful oncogenic factors. Blocking glucose metabolism, or shifting cellular 
metabolism away from glycolysis, impairs YAP/TAZ transcriptional activity and 
their ability to promote cell proliferation, cancer cell self-renewal and clonogenic 
abilities in vitro, and tissue overgrowth in Drosophila. In line with this, 
growth/survival promoted by glucose incorporates YAP/TAZ activity as 
downstream effectors.  
Mechanistically, we found that phosphofructokinase 1 (PFK1), mediating the first 
committed step of glycolysis, interacts with the transcription factors TEADs to 
stabilize their interaction with YAP/TAZ. In so doing, glucose metabolism 
regulates the recruitment of YAP at target promoters, providing a rationale for the 
regulation of YAP/TAZ transcriptional activity. 
This study highlights some peculiarities of YAP/TAZ. Classical oncogenes such 
as Ras, Myc and HIFs actively induce metabolic reprogramming toward aerobic 
glycolysis15,20, while YAP/ TAZ are instead regulated downstream to changes in 
glucose and mevalonate metabolism34. Since YAP/TAZ are also regulated by cues 
embedded in the cell microenvironment (Hippo kinase cascade, ECM mechanics, 
cell-cell adhesion structures, GPCR and Wnt signaling), it is tempting to speculate 
that this mechanism might represent a way by which cell metabolism and tissue-
level information are integrated into a common output. YAP/TAZ also appear 
different from another transcription factor regulated by glucose, ChREBP/ 
MondoA: ChREBP mainly regulates expression of metabolic enzymes and thus 
serves as a feedback transcriptional mechanism to adjust enzyme levels to nutrient 
availability and to coordinate lipid and glucose metabolism7,11; YAP/TAZ instead 
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incorporate clues from glucose metabolism into cancer cell growth and self-
renewal. 
 
LINK	  BETWEEN	  GLUCOSE	  METABOLISM	  AND	  YAP/TAZ	  
ACTIVITY	  IN	  BREAST	  CANCER	  
 
An increase in glucose uptake and a shift toward aerobic glycolysis are commonly 
observed in several tumors. This is true for breast cancers, and in particular in 
mammary tumor-initiating cells (TICs) and undifferentiated basal-like mammary 
tumors (i.e. those mostly enriched in TICs) that require glycolysis for their self-
renewal ability90,91. Strikingly, aerobic glycolysis can be even sufficient, at least 
in vitro, to induce malignant phenotypes in breast cancer cells26. This parallels 
with YAP/TAZ activity, which is increased in high-grade (G3 vs. G1) tumors and 
is functionally required for CSC self-renewal, tumor-seeding ability and 
aggressiveness45. Thus, the link between YAP/TAZ and glucose metabolism 
appears particularly relevant in breast cancer. Functionally, we showed that 
aerobic glycolysis is key to regulate YAP/TAZ-induced mammosphere formation 
and colony-forming ability. Accordingly, we also found that genes regulated by 
glucose showed a significant enrichment in high-grade tumors, and inversely 
correlated with disease-free progression in a large dataset of primary human 
breast cancers, closely overlapping YAP/TAZ activity. Interestingly, different 
studies identified that a high expression of PFK1 correlates with poor prognosis in 
primary breast cancers26. In line, a small-molecule inhibitor of PFKFB3 showed a 
striking inhibitory effect on the growth of mammary cancer cells in orthotopic 
assays95. This may indicate that YAP/TAZ activity in breast cancer tumor-
initiating cells might be particularly susceptible to therapeutic approaches 
targeting glycolysis. 
Collectively, our and other findings suggest that YAP/TAZ oncogenic activity 
needs to be coordinated with cell metabolism to efficiently drive cell growth. 
Infact YAP/TAZ are powerful inducers of proliferation, but this activity would be 
unleashed only when cells are in the right metabolic conditions to sustain cell 
growth. This would perhaps assign to cancer cells undergoing metabolic 
reprogramming (for example in response to oncogene activation, or to hypoxia) a 
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further selective advantage in terms of proliferation potential, survival, and tumor-
seeding ability. 
 
REGULATION	  OF	  YAP/TAZ	  BY	  AMPK	  	  
Recently, other three publications have described a connection between glucose 
metabolism and YAP/TAZ activity. These groups independently found that 
activation of AMPK by the use of small-molecule compounds (such as 
metformin, phenformin or AICAR) induces an increase in YAP phosphorylation 
at S127, favors YAP localization to the cytoplasm, and inhibits selected 
YAP/TAZ target genes96–98. To explain this common observation, different 
biochemical mechanisms were proposed: one study provided evidence that 
AMPK phosphorylates AMOTL1 and increases LATS1 activity, such that 
AMOTL1 knockdown can rescue YAP nuclear exclusion upon phenformin 
treatment96. In the second study, AMPK directly binds YAP and phosphorylates it 
mainly on S61 (and also on S94 and T119), but also promotes LATS1/2 activity 
and YAP S127 phosphorylation97. The third publication largely overlapped with 
the second one, but identified S94 as the major direct AMPK target on YAP98. 
The finding of a direct phosphorylation on S94 is noteworthy because this residue 
is key for YAP-TEAD interaction78, providing a direct explanation for the 
observation that AICAR inhibits YAP-TEAD complex formation. Bringing 
together all biochemical observations, activation of AMPK can thus induce both 
direct and LATS-dependent YAP phosphorylation events. As for the functional 
relevance of the AMPK-YAP axis, DeRan et al. showed that AMPK activation 
opposes a YAP-driven growth phenotype, acting through S127 phosphorylation96. 
Mo et al. showed instead that AICAR inhibits endogenous YAP target genes and 
clonogenic activity in LATS1/2 knockout MEFs (i.e. lacking of any S127 
phosphorylation)98, which instead indicates that AMPK works independently of 
LATS1/2. However, the requirement of AMPK for the regulation of YAP/TAZ by 
glucose remains unclear in functional terms: direct inhibition of YAP/TAZ by 
AMPK activators gave inconsistent results depending on the cell line, despite 
efficient AMPK modulation. Indeed, Wang and colleagues showed a partial 
rescue of YAP/TAZ activity by using AICAR compound to inhibit AMPK in 
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HEK293A cells deprived of glucose97. In contrast, as shown in Fig. 7E-F, we did 
not rescue YAP/TAZ inhibition by blocking AMPK activity in MDA-MB-231 
cells treated with 2DG, and we could not rescue YAP/TEAD protein-protein 
interction as well (data not shown). Thus, the possibility exists that regulation of 
YAP/TAZ by glucose entails multiple parallel mechanisms, included but not 
limited to AMPK. 
It should also be considered that AMPK is not a general and bona-fide tumor 
suppressor. AMPK is a powerful regulator of autophagy, and the AMPK-
autophagy axis plays a dual role in carcinogenesis: in some systems AMPK-
autophagy favors cancer cell survival under stress, and can thus have 
protumorigenic functions99,100, which are however not easily compatible with a 
general YAP/TAZ inhibitory role. For example, AMPK is activated in breast 
cancer cells forming mammospheres in absence of matrix attachment, and this 
activity is required for anoikis resistance; moreover, in these conditions AMPK 
activation is sufficient to promote malignant phenotypes, such as loss of polarity 
and luminal filling, typically promoted by oncogenes101–103. Of note, all these 
phenotypes are hallmarks of YAP/TAZ activation45,79, suggesting that AMPK and 
autophagy do not inhibit YAP/TAZ in these systems/conditions. 
 
YAP/TAZ-­‐TEADs	  PROTEIN	  COMPLEX	  	  
The finding that glucose metabolism intersects YAP/TAZ signaling at the level of 
TEAD factors underscores the idea that TEADs are central players for the 
regulation of YAP/TAZ. Indeed, recent findings indicate that disruption of YAP-
TEADs interaction may be a promising therapeutic strategy against YAP-driven 
human cancers41,42. This builds along a growing series of evidence indicating the 
importance of TEADs for YAP/TAZ function, and in particular for their pro-
tumorigenic activity. 
Both in Drosophila and in mammalian systems, TEADs normally interact with 
transcriptional inhibitors, such as the TGI and VGLL4 Tondu-domain containing 
proteins, and YAP/TAZ replace these factors to activate gene transcription42,104. In 
future, it will be interesting to understand how these cofactor exchanges are 
reciprocally regulated, and whether these occur while TEAD factors are on or off 
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DNA.  
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Introduction	  	  	  
NUCLEOTIDE	  BIOSYNTHESIS	  	  
Deoxyribonucleoside triphosphate (dNTP) metabolism is a fundamental pathway 
providing the essential substrates for DNA synthesis, both in the nucleus and in 
mitochondria. As a consequence, the size and composition of 
deoxyribonucleoside triphosphate (dNTP) pools is tightly regulated during the 
cell-cycle phases: during S-phase, total dNTP amounts peak roughly 10-fold 
higher then in G0/G1, to support DNA replication. For this, a series of enzymes 
involved in dNTP biosynthesis are specifically transcribed during S-phase in 
response to mitogenic stimuli. During the cell’s whole life, a smaller amount of 
dNTPs is produced, which is sufficient for DNA repair and mitochondrial DNA 
(mtDNA) synthesis105. Reflecting the central role of dNTP metabolism, both 
excessive and defective production of dNTPs can influence DNA replication, 
including origin choice, fork speed and inter-origin distance. As such, a proper 
dNTP concentration is one key factor enabling cell progression through the S-
phase. Maintenance of the proper dNTP concentration is essential not only to 
ensure a proper DNA replication and cell proliferation, but play significant roles 
also to prevent replicative mutagenesis, the stall of DNA replication forks, and the 
risk of DNA breaks: defects in dNTP metabolism can indeed increase the DNA 
mutation rate and genomic instability106–108. 
Nucleotides can be generated by two processes: de novo production and the 
salvage pathway. In the de novo synthesis, glucose and glutamine represent the 
main sources of carbons and nitrogen to produce nucleotides. The ribonucleoside 
diphosphate reductase (RNR) enzyme catalyzes the rate-limiting step of the 
pathway, synthetizing dNTPs de novo from ribonucleotides. The salvage pathway 
instead enables the recycling of both purine and pyrimidine free rings from 
turnover of cellular materials, to maintain the proper dNTP concentrations108. 
RNR is a heterotetrameric complex consisting of two large catalytic subunits 
(RRM1) and two small regulatory subunits (RRM2 or p53R2), and it catalyzes the 
reduction of each ribonucleoside diphosphate into deoxynucleotides. Because of 
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its critical importance, RNR is tightly regulated by several mechanisms, including 
allosteric regulation of the enzymatic complex and modulation of the levels and 
subcellular localization of its subunits. The transcription of RRM1 and RRM2 is 
generally promoted when cells enter into the S-phase thanks to activation of E2F 
factors, resulting in expansion of the dNTP pools108. Upon leaving S-phase, these 
two subunits are expressed at much lower levels. Moreover, the RRM2 is targeted 
to proteasome-dependent degradation during late mitosis. It is generally 
considered that the levels of the RRM2 subunit, more than RRM1, are key to 
control dNTP production during DNA replication: its expression is indeed rate-
limiting for RNR activity. p53R2 is a p53-inducible, DNA damage-responsive 
gene, which encodes for an alternative subunit to RRM2. The RRM1-p53R2 
complex provides dNTPs for DNA repair and mtDNA synthesis105,107. 
 
SENESCENCE	  	  
In 1961 Leonard Hayflick and Paul Moorhead were the first to describe the 
process of cellular senescence109. They observed that normal cells can divide a 
certain number of times, and then stop dividing. Cellular senescence is defined as 
a state of permanent cell-cycle arrest. At difference with quiescent cells, senescent 
cells are incapable of resuming proliferation, even upon mitogenic stimulation110. 
Replicative senescence has been observed in several primary cell types including 
epithelial, stromal (fibroblasts) and vascular (endothelial) cells. The maximal 
number of cell divisions that a cell population can perform before undergoing 
senescence is called the “Hayflick limit”. This limit is tightly linked to shortening 
of the telomeres that occurs upon repeated cell division cycles, which is thought 
to function as a molecular clock111. Cell populations that normally need to 
preserve long-term proliferation potential, such as stem cells, usually express high 
levels of TERT (telomerase reverse transcriptase), the enzyme enabling the 
elongation of telomeres during S-phase. Cells can enter into a senescent state not 
only as a consequence of repeated cell divisions, but also as a defense against 
stressful situations, including non-telomeric DNA damage, oxidative stress, 
perturbations to chromatin organization, excessive mitogenic signals, such as 
those produced by oncogene activation that are commonly associated with or 
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instrumental for cell transformation110. Senescence is thus considered a tumor-
suppressive mechanism intrinsically limiting the proliferation potential of cells. 
However, cancer cells loose the ability to undergo cell senescence by several 
mechanisms, including de novo expression of TERT and mutation of tumor-
suppressor genes involved in the activation of the senescent state110 (see below). 
Hallmarks	  of	  senescence	  
 
Cells undergoing senescence display a series of characteristic traits beyond a 
stable growth arrest, which include both morphological features (such as cell 
spreading and a bigger nucleus) and a distinctive pattern of gene expression. 
Senescent cells display activation of cell cycle inhibitors including the cyclin-
dependent kinase inhibitors (CDKIs) p21, p15 and p16112. p21 is activated in 
response to activation of the p53 pathway and, together with p16 and p15, 
activates pRb (Retinoblastoma) signaling. While p21 and p15 are generally 
regulated during cell-cycle arrest (for example in response to DNA damage or to 
anti-mitogenic signaling), the concurrent activation of p16 is considered a 
hallmark of senescence. Indeed p16 is not only a marker of senescence, but a 
required element for the establishment of the senescent state110,113. Senescent cells 
also inhibit genes that encode for cell cycle progression factors, including cyclins, 
CDKs (cyclin-dependent kinases) and origin-recognition factors of the MCM 
family. At least in part, repression of these pro-proliferative genes is linked to 
inhibition of E2Fs, a family of transcription factors that specifically promotes the 
expression of genes involved for G1/S transition112,114. 
A general marker of senescence, unrelated to cell proliferation regulation, is 
senescent-associated β-galactosidase (SA-βgal). SA-βgal reflects an increase in 
lysosomal biogenesis that occurs in senescent cells, leading to the appearance of 
lysosomal β-galactosidase activity. However, SA-βgal is induced also by stresses, 
such as cell confluence or oxidative stress115. Other phenotypes associated with 
senescence are the condensation of nuclear heterochromatin into discrete and 
dense foci, called senescence-associated heterochromatin foci (SAHF), and the 
general up-regulation of genes encoding for secreted cytokines and growth factors 
that are defined as SASP (senescence associated secretory phenotype)110,112. The 
function of these secreted proteins is both cell-autonomous, by installing a feed-
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forward loop that maintains cell senescence, and non cell-autonomous, by altering 
the cell microenvironment through remodeling of the extracellular matrix and 
recruitment of inflammatory cells116. Thus, senescence is defined by a series of 
distinct phenotypes, which are activated and regulated by different signaling 
pathways acting in parallel. It is also important to note that, among the markers of 
senescence so far presented, no one is exclusive to the senescent state and thus 
sufficient to define a senescent phenotype. 
Oncogene-­‐Induced	  Senescence	  	  
As anticipated above, a number of different stimuli can induce cellular 
senescence. These include critically shortened telomeres, DNA damage 
(especially double strand breaks – DSBs) and oncogene activation110,112,116. 
Oncogene-induced senescence (OIS) is the response of primary mammalian cells 
to oncogene activation. This paradoxical phenomenon has been mainly observed 
upon activation of mutated Ras (Hras or Kras) in normal fibroblasts. Ras is a 
cytoplasmic transducer of mitogenic signals that leads the activation of the 
MAPK/ERK and PI3K signaling cascades. Accordingly, other upstream or 
downstream members of the pathway were described to cause senescence when 
overexpressed or activated, including ERBB2/Neu, RAF and MEK. In this case, 
senescence is thought to occur in response to excessive mitogenic stimulation, 
acting as a tumor-suppressor to avoid oncogenic transformation. Findings in 
mouse cells support this idea: cells cultured in serum-free medium (i.e. with low 
mitogenic pressure) resist Ras-induced senescence110,112,114. 
Oncogene-induced senescence (OIS) by Ras activation was originally identified in 
cultured cells117 and has been a key model system for the study of senescence and 
of the pathways underlying its development. The relevance of OIS for real tumors 
is based on several observations, which indicate that senescence indeed plays a 
key tumor-suppressive role also in human tumors. Senescence markers, including 
p16 and SA-βgal activation, can be observed in early-stage tumors caused by Ras 
activation, either in genetically engineered mouse models for cancer or in human 
primary tumors117. For instance, human melanocytes bearing activating mutations 
of Braf are thought to escape from melanoma formation by forming benign nevi, 
which contain senescent cells118. Moreover, mutation of the locus encoding for 
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p16INK4a, p15INK4b and p19ARF is very often observed in human tumors 
bearing Ras or Braf activation, is a prerequisite for tumor progression in several 
genetic mouse models induced by Ras, and is prevalently observed in more 
advanced tumors, which correlates well with the idea that senescence represents 
an early barrier for tumor progression119. 
Role	  of	  dNTP	  metabolism	  in	  OIS	  
 
Upon oncogene activation, the excessive replication rates lead to aberrant DNA 
replication events, including fork collapse and asymmetric replication forks 
progression. Stresses during DNA replication in turn lead to activation of the 
DNA damage response (DDR), which has been shown to be required for OIS 
induction120. DDR indeed activates both the p53/p21 and p16/pRb pathways, thus 
inducing a stable cell cycle arrest. Recent findings suggest that DNA replication 
stresses and OIS, observed upon Ras activation, are due to contradictory 
regulation of dNTP metabolism: while on one hand Ras acts as a mitogen and 
promotes cell-cycle progression, at the same time it inhibits the transcription of 
key dNTP metabolism genes, including RRM2121,122. 
Interestingly, dNTP deficiency is required and sufficient, to some extent, for the 
establishment and maintenance of OIS-associated growth arrest120–122. This was 
shown by the finding that restoration of dNTP levels by exogenous nucleosides 
addiction or by ectopic RRM2 expression is sufficient to overcome activation of 
the DDR response and of OIS-associated growth arrest121.  
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Rationale	  	  
 
YAP/TAZ are powerful regulators of cell proliferation. Which are the genes and 
cellular mechanisms by which YAP/TAZ sustain cell proliferation remains largely 
unknown. Recently, extensive gene expression profiling of cancer cells upon 
depletion or overexpression of YAP and/or TAZ have been carried out27,31,47. 
Analysis of the genes regulated by YAP/TAZ indicates a widespread regulation of 
genes and programs linked to cell-cycle regulation, including origin-licensing 
factors, genes involved in DNA replication and, only to a minor extent, G1/S 
cyclin-CDK complexes1,53, raising the question of how YAP/TAZ regulate cell-
cycle progression at the beginning of the S-phase. Among other categories of 
regulated genes we then noticed the regulation of several genes involved in dNTP 
metabolism, including key enzymes involved in both the de novo and salvage 
dNTP synthesis pathways (Fig. 15A). Among these, we previously validated TK1 
(thymidine kinase), RRM2, RRM1, TYMS (thymidilate synthase) as bona-fide 
transcriptional targets of YAP/TAZ. Moreover, these genes are almost invariably 
contained in the gene signatures used to infer YAP/TAZ activation status in 
primary tumors by means of bioinformatics analysis such as GSEA31,45,123, 
indicating they are part of a core transcriptional program associated to YAP/TAZ 
driven malignancy. Of note, this regulation appears direct, because recent 
genome-wide analysis of YAP/TAZ binding sites revealed that YAP/TAZ bind 
the enhancer of most of these genes53. In line, we and others demonstrated by 
chromatin immunoprecipitation assay that YAP/TAZ bind to the TK1 and RRM2 
promoter (Fig.11A-B and 53). Moreover, as shown in Fig. 11C-D, we found that 
the isolated proximal TK1 promoter, containing the YAP/TAZ binding site, is 
responsive to experimental manipulation of YAP/TAZ levels and activity. By RT-
PCR or based on published microarray data, we also found that regulation of key 
dNTP metabolism enzymes occurs in several cellular systems (breast cancer, 
hepatocellular, mesothelioma, skin cancer), indicating a general mechanism (Fig. 
4A-B and 124,125). 
Given these observations, and based on the finding that dNTP metabolism is key 
not only for cancer cell proliferation, but also to overcome the senescence-
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associated growth arrest phenotype121,122, we asked whether YAP/TAZ, by 
sustaining dNTP biogenesis, can play a role in preventing OIS and OIS-associated 
growth arrest. This would help explain why YAP/TAZ activation potently 
predisposes tumor development in several tissues and why YAP/TAZ activity is 
required in several set-ups for transformation by oncogene activation. The 
regulation of RRM2 and dNTP metabolism by YAP/TAZ might thus be central 
during transformation and tumor initiation, but also in later phases of tumor 
development, given the continued requirement for DNA building blocks observed 
in cancer cells and tumors. 
Thus, the aim of the experiments presented hereafter is to explore the potential 
connections between YAP/TAZ activity, dNTP metabolism and OIS. 
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Preliminary	  Results	  	  	  
NUCLEOTIDE	  METABOLISM-­‐RELATED	  GENES	  ARE	  BOTH	  
YAP/TAZ	  AND	  RAS	  TARGETS	  
 
The most fundamental trait of senescent cells is growth arrest. Nucleotide 
metabolism and dNTP levels are crucial in regulating DNA replication and, in 
turn, cell proliferation. RNR is crucial for dNTP biosynthesis and its regulatory 
subunit RRM2 is rate-limiting for this process110. Recently, Aird and colleagues 
reported that establishment of the OIS-associated cell growth arrest correlates 
with and requires downregulation of dNTP metabolism, such that expression of 
oncogenic Ras in human normal fibroblasts downregulates the expression of 
dNTP synthesis enzymes, and that sustaining expression of RRM2 can prevent, to 
a certain extent, OIS-associated DDR and growth arrest121. 
We first asked whether YAP/TAZ regulate expression of dNTP metabolic 
enzymes not only in transformed cancer cells, but also in primary cells relevant to 
study OIS. For this, we experimentally manipulated the expression levels of 
YAP/TAZ in WI38 human fibroblasts by siRNA-mediated knockdown of 
YAP/TAZ or by retroviral overexpression of an activated form of YAP (YAP 
5SA), and monitored expression of RRM2, TK1 and TYMS expression by qPCR. 
As shown in Fig. 15B, YAP/TAZ positively regulate the expression of dNTP 
metabolic enzymes in WI38 cells. As a control, expression of activated Ras 
(HrasG12V) inhibited expression of RRM2121 and also of TK1 and TYMS. In 
parallel, we validated by qPCR in the same samples other established YAP/TAZ 
target genes such as Cyr61, ANKRD1 and AXL53,126 (Fig. 15C). Effective 
regulation of endogenous YAP, TAZ or Ras levels were checked by western 
blotting or qPCR analysis (Fig. 15D-E). Collectively, these results suggest that 
YAP/TAZ regulate the transcription of metabolic enzymes involved in dNTP 
biosynthesis in human primary fibroblasts. 
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YAP	  EXPRESSION	  OVERCOMES	  RAS-­‐INDUCE	  SENESCENCE	  	  	  
 
We next sought to determine whether YAP overexpression is sufficient to restore 
transcriptional levels of RRM2, TK1 and TYMS in fibroblasts infected with Ras. 
For this, we generated retroviral constructs enabling co-expression of both Ras 
and constitutive active YAP (YAP 5SA) from the same plasmid (using an internal 
ribosome entry site (IRES) sequence; as a control, we generated a Ras-IRES-GFP 
construct. qPCR analysis of WI38 cells infected with Ras-IRES-GFP or Ras-
IRES-YAP 5SA indicates that YAP overexpression is sufficient to reestablish the 
expression of RRM2, TK1 and TYMS at levels comparable to those present in 
normal fibroblasts (Fig. 16A), suggesting reactivation of dNTP metabolism. Of 
note, we observed that not only dNTP metabolic enzymes but also other 
YAP/TAZ target genes were inhibited upon Ras activation, which was rescued by 
activated YAP (Fig. 16B). Given that, Ras does not inhibit endogenous YAP and 
TAZ transcription or translation (Fig. 16C and data not shown), this suggests the 
possibility that during Ras-induced senescence endogenous YAP/TAZ function is 
inhibited. We also performed a direct measure of dNTP levels in our cells to assay 
for effective regulation of dNTP metabolism, and a preliminary experiment 
indicates this is the case (Fig. 16D).  
Does then YAP overexpression rescues only expression of selected genes, or 
globally interferes with Ras-induced senescence? To answer this question, we 
monitored by qPCR the expression of established senescence marker genes, such 
as the CDKIs and cyclins. As shown in Fig. 17A, YAP activation inhibited the 
expression of p21 and p15 to levels similar to control cells, and increased 
transcription of cyclin A2, cyclin B1 and cell division cycle associated 7 
(CDCA7). By western blotting, we found that YAP expression rescued normal 
levels of RRM2, cyclin A2 and lamin B (Fig. 17B), the latter being another 
hallmark of Ras-induced senescence127. We instead failed to observe 
downregulation of p16 (Fig. 17A), despite efficient induction of other senescent-
associated phenotypes (see below). 
We finally explored if YAP could oppose other hallmarks of senescent cells, such 
as growth arrest, SA-βgal expression and SAHF formation. As shown in Fig. 17C-
E, YAP rescued both Ras-induced growth arrest (as measured by EdU 
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incorporation assays), SA-βgal expression and SAHF formation, suggesting that 
YAP expression is sufficient to overcome a large part of senescence phenotypes. 
Of note, all these phenotypes require the regulation of dNTP metabolism by Ras, 
further reinforcing the idea that YAP is a relevant regulator of dNTP metabolism. 
 
YAP	  DEPLETION	  INDUCES	  SENESCENT	  PHENOTYPE	  
 
We started our experiments to test whether YAP regulates dNTP metabolism in 
an experimental set-up, such as OIS, where dNTP metabolism plays a primary 
functional role. In the course of our analysis, we noted that Ras activation not 
only inhibit dNTP metabolism, as reported by others107,108, but also a series of 
direct and established YAP/TAZ target genes. We thus asked whether YAP 
inhibition is sufficient to induce senescence in the same cells. For this we depleted 
WI38 cells of YAP by siRNA transfection, and monitored senescent phenotypes 
after 5 days, which is the usual time-window required for establishment of OIS 
upon Ras expression121 and when YAP protein levels were still clearly 
downregulated (Fig. 18A). These analysis were performed by transiently 
transfected siRNA against YAP, whose specificity was previously validated in the 
lab through a rescue experiment. Perhaps not surprisingly, YAP silencing caused 
inhibition in cell proliferation (Fig. 18B), as observed in many other cells. 
However, as shown in Fig. 18C-D, YAP depletion also significantly induced both 
the SA-βgal activity and SAHF formation. This was accompanied by regulation of 
senescence markers such as lamin B, cyclinA2 and RRM2, as checked by western 
blot (Fig. 18A) and by induction of p21 and p16 transcriptional levels (Fig. 18E). 
These results indicate that in absence of YAP activity, human primary fibroblasts 
undergo a phenotype strongly reminiscent of cellular senescence. 
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Discussion	  and	  Future	  directions	  	  
 
Our preliminary results indicate that YAP/TAZ can regulate dNTP metabolism in 
several cellular systems, and that this regulation is functionally relevant in the 
context of OIS. Indeed YAP expression in cells undergoing Ras-induced 
senescence is sufficient to reactivate expression of key dNTP metabolic enzymes 
whose expression is required and sufficient to oppose OIS. Accordingly, YAP can 
inhibit a series of phenotypes associated with Ras-induced senescence, including 
growth arrest, induction of SAHF, increased SA-βgal activity, and regulation of 
established senescence markers such as CDK inhibitors and cyclins. In future we 
plan to understand whether regulation of dNTP metabolism is required for the 
ability of YAP to prevent OIS. For this, we will test whether RRM2 and/or other 
YAP-regulated enzymes involved in nucleotide metabolism are required for YAP-
induced phenotypes. 
It also remains to be determined whether YAP can also modulate other 
phenotypes usually associated to OIS, such as expression of senescence-
associated secretory proteins. Given that induction of SASP is considered as a 
parallel pathway to oncogene-induced growth arrest112,116, this might indicate us 
whether YAP intercepts general induction of senescence, or more specifically the 
pathway(s) regulating growth arrest.  
Then we will address the possibility that nucleotide metabolism represents a 
general subset of YAP/TAZ-induced target genes to promote cell growth and 
cancer progression. Published evidence indeed suggests that sustained levels of 
RRM2 are required in transformed cancer cells to support proliferation and 
oppose the emergence of senescent traits128. For this, we will test if inhibition of 
dNTP metabolic enzymes is sufficient to inhibit YAP/TAZ pro-tumorigenic 
functions and, if so, whether the expression of RRM2, alone or in combination 
with other limiting enzymes of the pathway, is able (at least to a certain extent) to 
rescue proliferation in cells depleted of YAP/TAZ. Moreover, regulation of dNTP 
metabolism by YAP might underlie the ability of YAP-overexpressing cancer 
cells and tumors to display increased resistance to chemotherapy involving the use 
of dNTP metabolism inhibitors, such as gemcitabine107. Clearly YAP/TAZ 
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regulate a wide number of genes involved in DNA replication, cell division and 
survival, so it is likely that dNTP metabolism will not entirely account for 
YAP/TAZ pro-proliferation functions.  
As a corollary of these experiments, we found that YAP transcriptional targets are 
widely downregulated upon Ras activation, suggesting that inhibition of YAP 
activity is part of the mechanisms involved in OIS. In line with this idea, we 
found that loss of YAP induced the emergence of senescent traits in normal 
fibroblasts. Based on current knowledge, we will test a series of hypotheses by 
which Ras could oppose YAP during OIS. One possibility is that Ras might 
impact YAP/TAZ by inducing LATS activity or other direct post-translational 
regulatory mechanisms. Another possibility is that activation of pRb during the 
establishment of senescence, and thus inhibition of E2F factors, might result in 
inhibition of YAP transcriptional activity; this would be in line with recent 
findings indicating an intimate relationship between the pRb/E2F and YAP/TAZ 
activities40,129. 
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Materials	  and	  Methods	  	  
REAGENTS	  AND	  PLASMIDS	  
D-Luciferin, 2-deoxy-D-glucose, Lonidamine, Cerivastatin, DL-mevalonic acid 5-
phosphate, DON, AZS, GlcNAc, D-mannose, D-galactose, D-Luciferin, 
LatrunculinA and Verteporfin were from Sigma. CPRG was from Roche. 
Coelenterazine was from LifeTechnologies. 
8XGTIIC-luciferase plasmid is Addgene 34615. The Renilla luciferase version 
was derived by subcloning of the promoter region into promoterless pRLuc. 
CTGF-luciferase was created by amplifying the genomic region corresponding to 
-225bp from the TSS of the human CTGF promoter, containing three TEAD-
binding elements and the TATA box, into pGL3b. TK1-luciferase was created by 
amplifying the genomic region corresponding to -552bp from the ATG of the 
human TK1 locus; the two predicted TEAD-binding elements start at -200 and -
453. Doxycycline-inducible reporter systems were obtained by subcloning the tet-
responsive element from FudeltaGW plasmid upstream of the promoter-luciferase 
elements into a puromycin-resistant retroviral backbone. rtTA was subcloned 
from Addgene 19780 into pBABE-hygro. NF2/Merlin plasmid is Addgene 19699. 
WT and Y429H MYC-TEAD4 plasmids are Addgene 24638 and 33041. WT and 
F2,6P mutant FLAG-PFK1 isoform P plasmid was subcloned from Addgene 
23869. Mutation of the F2,6P allosteric site of PFK1 was carried out based on73,74  
and entails the following mutations: R481A, R576A, R665A, H671A, R744A 
(reference sequence is NP_002618). PFKFB3 was subcloned from Addgene 
23668. Plasmids encoding GAL4 fusions of WT or Y406A TEAD1 are Addgene 
33108 and 33034. GST-YAP and GST-TEAD4 plasmids were obtained by 
standard subcloning. For details on CMV-lacZ, RBPJ-luciferase, 6XE2F-
luciferase and UAS-luciferase see1. All plasmids were sequence-verified prior to 
use. 
pBABEpuro Hras V12 were from Addgene 39526. pBABEpuro YAP 5SA was 
generated by subcloning YAP 5SA from pcDNA332. The other retroviral 
constructs were generated by subcloning IRES-GFP, IRES-YAP 5SA in 
pBABEpuro Hras V12. pBABEpuro empty vector was used as control retroviral 
transduction. 
siRNA oligos were standard dsRNA oligos with overhanging dTdT from 
LifeTechnologies. Hereafter, targeted sense sequence of the mRNA:  
                   
 
 
siYT1 were used with YAP1 and TAZ1; siYT2 were used with YAP2 and TAZ2; 
siLATS1/2 were used with LATS1 and LATS2; siAMPKa1/2 were used with 
siRNA Interfering sequence siRNA Interfering sequence
YAP 1 GACAUCUUCUGGUCAGAGA PFK1 1 GGAGAACCGUGCCCGGAAA
YAP 2 CUGGUCAGAGAUACUUCUU PFK1 2 CGGGCAACCUGAACACCUA
TAZ 1 ACGUUGACUUAGGAACUUU LATS1 CACGGCAAGAUAGCAUGGA
TAZ 2 AGGUACUUCCUCAAUCACA LATS2 CAUACGAGUCAAUCAGUAA
GPI 1 GUUUGGAAUUGACCCUCAA AMPKa1 CACGAUAUUCUGUACACAA
GPI 2 GCUUGAUGGCAGUGCUCAA AMPKa2 GAAGUCAGAGCAAACCGUA
AMPKa2 
2 GGAAGGUAGUGAAUGCAUA
AMPKa1 
2 GGGAUCAGUUAGCAACUAU
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AMPKa1 and AMPKa2. Control siRNAs were Qiagen AllStars Negative Control 
siRNA or a 1:1:1 mix of Scramble, GFP and Luc* siRNAs, which were used 
back-to-back, with results comparable to non-transfected cells.  
CELL	  CULTURE,	  TRANSFECTIONS	  AND	  INFECTIONS	  
MCF10A, MCF10A-MII and MCF10A-MII-TAZ-S89A cells and their empty 
vector controls45 were cultured in DMEM/F12 supplemented of 5% Horse Serum, 
2mM Glutamine, Insulin, Cholera Toxin, Hydrocortisone and EGF; MDA-MB-
231 (STR verified) in DMEM/F12 with 10% FBS and 2mM Glutamine; Hs578T 
(ATCC) in DMEM with 10% FBS, 2mM Glutamine, Insulin; HEK293 (ATCC) in 
DMEM with 10% FBS and 2mM Glutamine; HepG2 (ATCC) in MEM with 10% 
FBS, 2mM Glutamine, NEAA; UOK262 in DMEM with 10% FBS, 2mM 
Glutamine and 1mM Pyruvate. WI38 human fibroblasts were cultured in MEM 
with 10% FBS and 2mM Glutamine. Cells were maintained in low oxygen (5%) 
till infection or transfection. All cells were routiney tested for mycoplasma 
contaminations with commercial PCR kits (Sigma).  
siRNA transfections were done with Lipofectamine RNAi MAX (Invitrogen). 
Plasmid DNA transfections were done with Transit-LT1 (MirusBio). Retroviral 
infections were carried out following standard procedures and protocols. 
Retroviral particles were prepared by transiently transfecting HEK293gp cells 
with retroviral vectors together with packaging vector (pMD2-env). Culture 
medium containing the viral particles was collected and filtered 48h after 
transfection. Viral infection was performed by incubating target cells with diluted 
viral supernatant for 24h. Infected cells were selected, 48h after infection, with 
puromycin. 
MAMMOSPHERE	  ASSAY	  
Mammosphere assay was carried out by plating 1000 cells for each 24-well, and 
by plating 4 wells replicates for each sample; primary mammospheres were 
counted after 6 days. Differences in cell viability at plating were excluded based 
on TUNEL assays (not shown). Mammospheres were dissociated in trypsin and 
an equal numer of single cells replated to grow secondary mammospheres.  
SOFT	  AGAR	  ASSAY	  
For soft agar assay, we plated 10000 MDA-MB-231 cells in triplicate in 35mm 
dishes in growth medium containing 0.3% low melting agarose, over a 0.6% 
agarose layer without cells; colonies were grown for 2 weeks (5SA-YAP 
expressing cells and their controls) or for 3 weeks (cells transfected with siRNA). 
WOUND	  ASSAY	  
Wound assay was performed by plating 1.5x106 MCF10A cells in 24-wells 
containing fibronectin-coated 13mm glass slides; after 24h, the cell monolayer 
was scratched with a sterile P1000 tip, washed and grown overnight. 2DG was 
added after washing. 
For clonogenic assay, we plated 800 UOK262 cells in a 35mm petri dish, in 
triplicate; after 10 days colonies were stained with crystal violet, photographed 
and counted with imageJ software by quantifying the total stained area. 
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ECAR	  AND	  OCR	  MEASUREMENTS	  
The XF24 extracellular flux analyzer (Seahorse Bioscience) was used to detect 
real-time changes in cellular respiration and glycolysis rates. Cells were cultured 
in standard XF24 plates, by seeding 120000 (MDA-MB-231) or 90000 
(MCF10A-MII) cells/well 24h before performing the measures; for experiments 
with siRNA, cells were transfected, reseeded after 24h, and measured after further 
24h. Analysis of the extracellular acidification rate (ECAR) reflects lactate 
secretion and serves as indirect measure of glycolysis rate; oxygen consumption 
(OCR) reflects cellular respiration and is directly determined. All measurements 
were performed following manufacturer’s instructions and protocols with at least 
4 biological replicates for each condition, and normalized to total protein content 
as determined by Bradford assays. The analysis was carried out by Dr. Giulia 
Guzzo (Unipd). 
REAL-­‐TIME	  PCR	  
Total RNA was extracted using RNeasy Mini Kit (Qiagen) and contaminant DNA 
was removed by RNase-Free DNase Set (Qiagen). cDNA synthesis was carried 
out with dT-primed M-MLV Reverse Trascriptase (LifeTechnologies). Real-time 
qPCR analyses were carried out with triplicate samplings of each sample cDNA 
on a Rotor-Gene Q (Qiagen) thermal cycler with FastStart SYBR Green Master 
Mix (Roche) and analyzed with Rotor-Gene Analysis6.1 software. Expression 
levels are calculated relative to GAPDH. Sequences of primers are the following: 
 
	  
Primers 
for qPCR
               sequenses
Primers 
for qPCR
                sequenses
GAPDH for  CTCCTGCACCACCAACTGCT CYP1B1 for TGGCTGCTCCTCCTCTTCAC
rev GGGCCATCCACAGTCTTCTG rev TGGGAATGTGGTAGCCCAAG
YAP for GCACCTCTGTGTTTTAAGGGTCT HMMR for AGCTGAAAGGGAAGGAGGCTG
rev CAACTTTTGCCCTCCTCCAA rev CAAGGCTTTGCACCATACTGTCA
TAZ for GGCTGGGAGATGACCTTCAC CTGF for AGGAGTGGGTGTGTGACGA
rev CTGAGTGGGGTGGTTCTGCT rev CCAGGCAGTTGGCTCTAATC
GPI for ACGCCATGCTGCCCTATGAC ANKRD1 for AGTAGAGGAACTGGTCACTGG
rev ATGCTGGCCATTGGTCCCTG rev TGGGCTAGAAGTGTCTTCAGAT
TYMS for AAACCAACCCTGACGACAGAA Cyr61 for CCTTGTGGACAGCCAGTGTA
rev GTTCACCACATAGAACTGGCAG rev ACTTGGGCCGGTATTTCTTC
RRM2 for CTGGCTCAAGAAACGAGGAC CRIM1 for CCATTGCCTCAGTTGTGGTTC
rev GTTTGAACATCAGGCAAGCA rev TGGTTCCTTTCTTGCAGTCCA
TK1 for TTGTGGCTGCACTGGATGGG AXL for CACCAGCAAGAGCGATGTGT
rev TCCTTCTCTGTGCCGAGCCT rev CGGTCCTGGGGATTTAGCTC
CDC25A for AGGGAGGCCACATCAAGGGT CDCA7 for GTTCGAGGCCAGTTCTGTGG
rev ACACGCTTGCCATCAGTAGGT rev AGTCGCACACCGTCCATCTC
AQP3 for TCGTGTGTGTGCTGGCCATT Cyclin A2 for TTTGATAGATGCTGACCCATACC
rev AGCCGGAGTTGAAGCCCATG rev ATGCTGTGGTGCTTTGAGGT
VSIG1 for TGGGGCCTTGATTGGTAGCC Cyclin B1 for CCCCTGCAGAAGAAGACCTG
rev TGCTTCGCTTTCTCCCCTTGG rev AGTGACTTCCCGACCCAGTA
TXNIP for ATGGGCGGGTGTCTGTCTCT p21 for CAGGAGGCCCGTGAGCGATGGA
rev TGGCAAGGTAAGTGTGGCGG rev ATCAGCCGGCGTTTGGAGTGGT
F3 for TGAAGGATGTGAAGCAGACG p16 for CGATGTCGCACGGTACCTG
rev CCGAGGTTTGTCTCCAGGTA rev TCAATCGGGGATGTCTGAGG
CDCA7 for GTTCGAGGCCAGTTCTGTGG p15 for GGACTAGTGGAGAAGGTGCG
rev AGTCGCACACCGTCCATCTC rev GGTGAGAGTGGCAGGGTCT
FST for CCGGTGTTCCCTCTGTGATG
rev TCCTCTTCCTCGGTGTCTTCC
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LUCIFERASE	  ASSAYS	  
For transient transfections, cells were typically plated in 24-well format and 
luciferase reporter plasmids were transfected with CMV-lacZ to normalize for 
transfection efficiency based on CPRG (Merck) colorimetric assay, together with 
plasmids encoding for the indicated proteins; DNA content was kept uniform by 
using pKS Bluescript. Cells were harvested in Luc lysis buffer (25mM Tris pH 
7.8, 2.5mM EDTA, 10% glycerol, 1% NP40). Luciferase activity was determined 
in a Tecan plate luminometer with freshly reconstituted assay reagent (0.5mM D-
Luciferin, 20mM Tricine, 1mM (MgCO3)4Mg(OH)2, 2.7mM MgSO4, 0.1mM 
EDTA, 33mM DTT, 0.27mM CoA, 0.53mM ATP). For stable cell lines, cells 
were plated in 12-well format and treated as indicated before harvesting; 
normalization was based on total protein content, as measured by Bradford assays. 
Each sample was transfected at least in two biological duplicates in each 
experiment to determine the experimental variability; each experiment was 
repeated independently with consistent results. 
DETERMINATION	  OF	  INTRACELLULAR	  dNTP	  POOLS	  
100mm dishes plated at 70% of confluence were cooled on ice. Cells were then 
carefully washed free of medium and extracted with ice-cold 60% methanol. After 
immersion for 3 min in a boiling water bath the methanolic extract was 
centrifuged and brought to dryness by centrifugal evaporation. The dry residue 
was dissolved in 0.2 ml of water and used for assays. We analyzed two aliquots of 
different size per each sample to ascertain linearity of the assay. The cells 
remaining after extraction were dissolved in 0.3 M NaOH. The A260nm of the 
NaOH fraction containing the cellular macromolecules left after pool extraction 
was used as an index of cell mass130. The sizes of the dNTP pools were 
determined with a DNA polymerase-based assay as in131 by Dr. Chiara Rampazzo 
and Dr. Elisa Franzolin (Unipd).  
MICROARRAYS	  AND	  GLUCOSE	  SIGNATURES	  
For microarrays of genes regulated by glucose uptake, cells were plated in 60mm 
plates, treated with 2DG and harvested after 24h. For YAP/TAZ regulated genes, 
cells were plated in 60mm plates, transfected with siRNA and harvested 48h after 
transfection. For each experimental condition, we prepared 4 biological replicates 
that were processed in parallel. Total RNA was extracted using RNeasy Mini Kit 
(Qiagen) and contaminant DNA was removed by RNase-Free DNase Set 
(Qiagen). RNA quality and purity were assessed on the Agilent Bioanalyzer 2100 
(Agilent Technologies); RNA concentration was determined using the NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technologies). As control of effective 
gene modulation and of the whole procedure, we monitored the expression levels 
of established markers (TXNIP for 2DG, CTGF and ANKRD1 for YAP/TAZ) by 
qPCR prior to microarray hybridization. Labeling and hybridization were 
performed according to Affymetrix One Cycle Target Labeling protocol on HG-
U133 Plus 2.0 arrays (Affymetrix). Microarray data are available at Gene 
Expression Omnibus under accession GSE59232. 
All data analyses were performed in R (version 3.0.2) using Bioconductor 
libraries (BioC 2.13) and R statistical packages. Probe level signals were 
converted to expression values using robust multi-array average procedure RMA 
of Bioconductor affy package. Differentially expressed genes were identified 
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using Significance Analysis of Microarray algorithm coded in the samr R 
package. In SAM, we estimated the percentage of false positive predictions (i.e., 
False Discovery Rate, FDR) with 100 permutations. 
To identify genes associated with high glucose uptake in cells of mammary origin 
(glucose signature), we compared the expression levels of MCF10A and MDA-
MB-231 cells grown in high glucose or in the presence of 2DG and selected those 
probe sets with a fold change ≤ -3 in both MCF10A and MDA-MB-231 
comparisons. This selection resulted in 298 probesets downregulated by the 
presence of 2DG in the culture medium. We then refined this selection 
eliminating from the glucose signature the genes that were also regulated upon 
knockdown of YAP/TAZ, i.e. removing 2DG-regulated genes with an FDR ≥ 
0.1% in the comparisons between YAP/TAZ depleted MCF10A and MDA-MB-
231 cells and their controls. 
To functionally annotate genes co-regulated by glucose and YAP/TAZ we 
consider the Biological Process Gene Ontology (GO) categories of the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) GO terms were 
considered significant at a confidence level of 95%. 
The analysis was carried out by Prof. Silvio Bicciato and Dr. Mattia Forcato 
(Unimore). 
DROSOPHILA	  ASSAYS	  
All the strains were obtained from the Bloomington Stock Center and grown 
under standard conditions. For Flippase activation, non-overcrowded cultures of 
48±6h after egg laying individuals grown at 25°C on standard medium were 
transferred to a water bath at 37°C for 20 minutes. After additional 72h at 25°C, 
larvae were dissected for analyses. Genotypes analysed were: yw,hs-Flp,tub-
Gal4,UAS-GFP/w; tub-Gal80,FRT40A/l(2)gl4,FRT40A; UAS-yki/+ and yw,hs-
Flp,tub-Gal4,UAS-GFP/w;  tub-Gal80,FRT40A/l(2)gl4,FRT40A; UAS-yki/UAS-
PfkRNAi. 
For immunostainings, larvae were dissected in PBS1X and carcasses were fixed, 
washed and immunostained following standard methods. Primary antibodies 
were: rabbit aPKC (Santa Cruz Biotechnology, 1:200), mouse DIAP1 (B. Hay, 
1:200) and mouse dMyc (P. Bellosta, 1:5). Secondary antibodies were: anti-mouse 
Alexa Fluor 555 (Life Technologies) and anti-rabbit DyLight CY5 (Jackson 
Immunoresearch). Wing discs were isolated, mounted in Vectashield (Vectorlabs) 
and images were acquired by Leica TCS SP2 confocal microscope. All figures 
show single, 1mm thick tissue sections. 
Clone areas (in pixel2) were measured using ImageJ free software (NIH) on 
images captured with 90i wide fluorescence microscope (Nikon). Areas of clones 
grown as multilayers are likely to be underestimated. Discs were scored for clones 
included in the wing pouch region for a total of 34 discs, and the average clone 
area was normalized to the wing pouch size. 
The analysis was carried out by Prof. Annalisa Pession and Prof. Daniela Grifoni 
(Unibo). 
ANTIBODIES	  AND	  MICROSCOPY	  
Antibodies were FLAG-M2 HRP- or agarose-conjugate (Sigma), YAP/TAZ 
(sc101199), YAP for IP (Abcam 52771), TAZ for IP (Sigma HPA039557), 
phospho S127 YAP (CST4911), PFK1 (Abcam 119796, sc130227 or CST5412), 
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TEAD1 (BD 610922), TEAD1 for IP (Abcam 133533), TEAD4 (sc101184), 
MYC (sc789), total S6 (CST2217), phospho S6 (CST5364), AMPK (CST2532), 
GAPDH (Millipore MAB374), Hras (sc-520), RRM2 (sc-10844), p21 (BD 
610234), Lamin B (sc-6216), Cyclin A2 (sc-596). 
For immunofluorescence, cells were fixed for 10 minutes in 4% PFA, washed in 
PBS and either stored dried at -80°C or directly permeabilized and processed for 
immunostaining as described in31. Proximity Ligation Assays were performed as 
indicated by the provider’s protocol (OLink Bioscience), after an overnight 
incubation with primary antibodies following our standard protocol. For PLA, 
antibodies were YAP (CST4912) and TEAD1 BD and PFK1 sc. pictures were 
taken at the confocal microscope by selecting the maximal nuclear section. 
Images were acquired with a Leica SP5 confocal microscope equipped with CCD 
camera using Volocity software (Perkin Elmer).  
For BrdU, cells were fixed and processed according to manifacturer’s instructions 
(BrdU cell proliferation kit, Merck) and images acquired with a Leica DM5000B 
microscope.  
SENESCENCE	  MARKERS	  ANALYSIS	  
Reference time frame for the analyses of senescence markers:  
Day 0: cellular selection with puromycin (48h after retroviral infection); Day 6: 
analysis of senescence markers (% S-phase, SA-βgal, SAHF, p16, p21, p15, 
cyclin A2, cyclin B1, CDCA7, lamin B).  
After the end of the selection cells were plated at low confluence in 13mm dishes. 
On day 6, cells were incubated with EdU (for analysis of the S-phase) for 1h 
before fixing them with 3,7% formaldehyde for 15min. Cells were then either left 
in PBS at 4°C (for few days only) or analyzed according to manifacturer’s 
instructions (Life Technologies). 
SA-βgal staining was performed on day 6 as previously described115. 
SAHF were visualized by DAPI staining on fixed cells. 
IMMUNOPRECIPITATIONS	  
For immunoprecipitations, cells were lysed in HPO buffer (50mM Hepes pH 7.5, 
100mM NaCl, 50mM KCl, 2mM MgCl2, 1% Triton X100, 0.5% NP40, 5% 
glycerol) with proteases (Merck) and phosphatases (Sigma) inhibitors, and 
homogenized by sonication (Diagenode Bioruptor). Extracts of equal total protein 
content and concentration were then subjected to immunoprecipitation with 
primary antibodies previously bound to proteinA-conjugated sepharose (GE 
Healthcare) in 2% BSA. Control IgG for pulldowns with anti YAP and anti 
TEAD1 rabbit antibodies was anti HA rabbit polyclonal (sc805). After 2,5h of 
incubation on a rotator at 4°C, beads were washed three times in the same buffer 
and the purified proteins were boiled in Laemli Final Sample Buffer for western 
blotting with species-specific secondary HRP-conjugated antibodies 
(ExactaCruz). 
For studies with recombinant proteins, GST-YAP and GST-TEAD4 were 
produced and purified from bacteria with standard protocols; FLAG-PFK1 and 
FLAG-TEAD1 were purified from HEK293 transfected lysates by anti-FLAG-M2 
immunoprecipitation, followed by elution with 3XFLAG peptide (Sigma). All 
proteins were dyalised in BC100. Proteins were mixed in HPO buffer with 5% 
BSA and incubated for 2h at 4°C, followed by another 30 min together with anti-
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FLAG-M2 agarose conjugated beads. Beads were washed three times in the same 
buffer and the purified proteins were boiled in Laemli Final Sample Buffer for 
western blotting.  
For mass-spectrometry of YAP interacting proteins, 50% confluent cultures 
(150mm dishes) of MCF10A or MDA-MB-231 cells stably expressing FLAG-
YAP-5SA were harvested in 1ml HPO buffer and homogenized by sonication. 
Controls were parental cells. Freshly prepared extracts from two sibling plates 
were joined and subjected to immunoprecipitation with agarose-conjugated FLAG 
M2 antibody for 2,5h at 4°C on a rotator. After three washes in the same buffer, 
immunopurified proteins were eluted by adding 3XFLAG peptide (Sigma) for 30 
min at 4°C, in order to reduce aspecific purification of proteins on agarose beads. 
Eluted proteins were run in a 4-12% MOPS-SDS gel (LifeTechnologies) to 
separate them from the elution peptides, fixed and stained with colloidal 
coomassie. The gel was sent to EMBL Proteomic Facility for in gel tryptic 
digestion and mass spectrometry. Proteins purified with similar frequency from 
control and FLAG-YAP expressing lysates were considered non-specific 
background; all other proteins were considered for further analysis. 
CHROMATIN	  IMMUNOPRECIPITETION	  
Cells were plated in duplicate, using two 150mm dishes for each replicate. After 
the indicated treatments, cells were crosslinked by adding to the culture medium 
1/10 of fresh formaldehyde solution (11% formaldehyde 0.1M NaCl, 1mM 
EDTA, 0.5mM EGTA, 50mM HEPES pH 7.5) for 10min at RT, followed by 
quenching with 125mM Glycine for 5 min. After washing in PBS, cells were 
harvested in PBS with protease inhibitors and pelleted for 5min at 1500rcf at 4°C. 
Cells were resupended in cold LB1 (10mM NaCl; 1mM EDTA; 50mM; HEPES 
pH 7.5; 10% Glycerol; 0.5% NP-40; 0.25% Triton-X-100) and incubated for 
20min; pelleted and resuspended in LB2 (10mM TRIS pH 8.0; 200mM NaCl; 
1mM EDTA; 0.5mM EGTA) and incubated for 10min; pelleted and resuspended 
in sonication buffer (10mM TRIS pH 8.0; 1mM EDTA; 100mM NaCl; 0.5mM 
EGTA; 0.1% NaDeoxycholate; 0.5% N-Lauroylsarcosine). Sonication was carried 
out with a Branson Sonfier 450 to obtain sheared chromatin of 200-600bp 
fragments. Effective sonication and quantification of the DNA to equalize 
samples was carried out on 1% of each sample after decrosslinking; this sample 
was also used as input control for qPCR. The same total amount of sheared 
chromatin per sample (in the range of 120mg) was supplemented with 1% Triton 
X100 and subjected to immunoprecipitation o.n. at 4°C with anti-YAP (Abcam) 
or with control rabbit IgG. ProteinA-dynabeads (LifeTechnologies) were added 
for 2h after extensive blocking in 0,5% BSA. Washes were (5min each): low salt 
(0,1% SDS, 2mM EDTA, 1% Triton X100, 20mM Tris pH=8, 150mM NaCl), 
high salt (500mM NaCl), low salt, high salt, TE + 50mM NaCl. 
Immunoprecipitated material was eluted from the beads by incubating 20min at 
65°C in TE + 1% SDS. Supernatant was decrosslinked o.n. at 65°C, diluted 1:2 in 
TE, treated 1h at 37°C with RNaseA (0.2mg/ml), followed by 1h at 55°C with 
ProteinaseK. After phenol-chloroform extraction and ethanol precipitation, DNA 
was resuspended in water for qPCR analysis. The amount of DNA present in each 
immunoprecipitate was quantified as the fraction of its input. Sequences of 
primers are the following: 
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OVER-­‐REPRESENTATION	  GSEA	  ANALYSIS	  	  
Over-representation analysis was performed using Gene Set Enrichment Analysis 
and gene sets derived from previously published gene signatures. For details see1 
GSEA software was applied on log2 expression data of MCF10A and MDA-MB-
231 cells grown in high glucose or in the presence of 2DG. Gene sets were 
considered significantly enriched at FDR<5% when using Signal2Noise as metric 
and 1,000 permutations of gene sets. The analysis was carried out by Prof. Silvio 
Bicciato and Dr. Mattia Forcato (Unimore). 
AVERAGE	  SIGNATURE	  EXPRESSION	  AND	  SIGNATURE	  SCORES	  
Average signature expression has been calculated as the standardized average 
expression of all signature genes in sample subgroups (i.e. 2DG treated/controls; 
histological grade). Signature scores have been obtained summarizing the 
standardized expression levels of signature genes into a combined score with zero 
mean. The values shown in graphs are thus adimensional. The analysis was 
carried out by Prof. Silvio Bicciato and Dr. Mattia Forcato (Unimore). 
COLLECTION	  AND	  PROCESSING	  OF	  BREAST	  CANCER	  GENE	  
EXPRESSION	  DATA	  	  
We started from a collection of 4.640 samples from 27 major datasets comprising 
microarray data of breast cancer samples annotated with histological tumor grade 
and clinical outcome. All data were measured on Affymetrix arrays and have been 
downloaded from NCBI Gene Expression Omnibus (GEO, and EMBL-EBI 
ArrayExpress). 
Prior to analysis, we re-organized all datasets eliminating duplicate samples and 
re-naming any original set after the medical center where patients were recruited. 
This re-organization resulted in a compendium (meta-dataset) comprising 3.661 
unique samples from 25 independent cohorts. The type and content of clinical and 
pathological annotations of the meta-dataset samples have been derived from the 
original cohorts. 
Since raw data (.CEL files) were available for all samples, the integration, 
normalization, and summarization of gene expression signals has been obtained 
applying the procedure described in132. Briefly, expression values were generated 
from intensity signals using a custom-CDF obtained merging HG-U133A, HG-
U133AAofAV2, and HG-U133 Plus2 original CDFs and transforming the original 
CEL files accordingly. Intensity values for a total of 21986 probe sets have been 
Primers for ChIP                       sequences
CTGF for TGTGCCAGCTTTTTCAGACG
rev TGAGCTGAATGGAGTCCTACACA
ANKRD1 for AAAAAGGGCAGTGATGTGGTG
rev GAAGAGGGAGGGGAGGACAA
HMMR for TGGAACCAGTGAAGCCGGAAC
rev CCTGCGAGTTTAGGCTGCCA
TK1 for TGGGCAGGTTAATGCAGCTC
rev CGGGAACCAGGGGCTTACT
HBB for GCTTCTGACACAACTGTGTTCACTAGC
(negative control) rev CACCAACTTCATCCACGTTCACC
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background adjusted, normalized using quantile normalization, and gene 
expression levels calculated using median polish summarization (multi-array 
average procedure, RMA). Clinical information among the various datasets has 
been standardized as described in45. The analysis was carried out by Prof. Silvio 
Bicciato and Dr. Mattia Forcato (Unimore). 
KAPLAN-­‐MEIER	  SURVIVAL	  ANALYSIS	  
To identify two groups of tumors with either high or low glucose signature we 
used the classifier described in133, i.e. a classification rule based on the Glucose 
signature score. Tumors were classified as glucose signature Low if the combined 
score was negative and as glucose signature High if the combined score was 
positive. This classification was applied to expression values of the meta-dataset. 
To evaluate the prognostic value of the glucose signature, we estimated, using the 
Kaplan-Meier method, the probabilities that patients would remain free of 
metastatic. To confirm these findings, the Kaplan-Meier curves were compared 
using the log-rank (Mantel-Cox) test. P-values were calculated according to the 
standard normal asymptotic distribution. Survival analysis was performed in 
GraphPad Prism. The analysis was carried out by Prof. Silvio Bicciato and Dr. 
Mattia Forcato (Unimore). 
STATISTICAL	  ANALYSIS	  
Statistical analysis were performed using Prism software (GraphPad Software). 
Mean values and standard deviations (SD) are shown in graphs that were 
generated from several repeats of biological experiments, unless otherwise 
indicated. Immunoprecipitation experiments were performed with n=2 biological 
replicates for each sample, and repeated at least two times independently with 
comparable results. The analysis was carried out by Prof. Silvio Bicciato and Dr. 
Mattia Forcato (Unimore). 
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Figures	  	  
FIGURE	  1.	  Exploring	  possible	  links	  between	  glucose	  metabolism	  and	  YAP/TAZ	  
activity	  	  
A) Over-representation analysis was performed with Gene-Signatures 
highlighting activation of specific pathways using Gene Set Enrichment Analysis 
(GSEA) on microarray data obtained from MCF10A or MDA-MB-231 mammary 
cells untreated or treated with 2-deoxy-glucose (2DG, 50mM) to inhibit glucose 
metabolism. The normalized enrichment score (NES) is the primary statistic for 
examining GSEA results; a positive NES (highlighted in red) indicates signatures 
expressed more in control cells than upon 2DG treatment (i.e. signatures activated 
when glucose metabolism is on); a negative NES (highlighted in blue) indicates 
signatures expressed more upon 2DG treatment. The false discovery rate (FDR) is 
the estimated probability that a gene set with a given NES represents a false 
positive; we considered signatures to be significantly enriched at FDR<0.05. Gene 
expression data has been obtained from n=4 biological replicates for each 
condition. 
 
B) 2DG treatment downregulates the overall levels of the “YAP/TAZ”, “YAP”, 
“induced by YAP” and “repressed by YAP” gene signature used in (A) as 
calculated from microarray data of cells untreated (white bars) or treated with 
2DG (black bars). Data are shown as mean ± standard error of the mean (SEM). 
 
C) The plot indicates basal oxygen consumption rate (OCR, indicative of 
mitochondrial respiration) and extracellular acidification rate (ECAR, indicative 
of aerobic glycolysis) of MCF10A and MDA-MB-231 cells as measured with an 
extracellular flux analyzer and normalized to total protein content. Representative 
results of a single experiment with n=5 biological replicates; 2 independent 
experiments were consistent. 
 
D) Representative traces of ECAR (left) and OCR (right) performed with an 
extracellular flux analyzer on monolayers of MCF10A-MII cells. Blue: control 
cells; red: cells stably expressing activated TAZ-S89A. Representative results of a 
single experiment with n=5 biological replicates; 2 independent experiments were 
consistent. 
Left: Cells were kept in glucose-free medium and subsequently supplemented 
with Glucose (10mM), with the ATP synthase inhibitor Oligomycin (0.8mM), 
with the Glucose inhibitor 2DG (100mM) respectively to enable glycolysis, to 
measure maximal glycolytic capacity, and to completely inhibit glycolysis.  
Right: Subsequent additions of the ATP synthase inhibitor Oligomycin (0.8mM), 
the uncoupler FCCP (900nM), the electron transport chain (ETC) complex I 
inhibitor Rotenone (1mM) and the ETC complex III inhibitor antimycin A (1mM) 
were carried out respectively to measure basal respiration (initial time points), 
respiration coupled to ATP production in mitochondria, maximal respiratory 
capacity and non-mitochondrial oxygen consumption.  
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FIGURE	  2.	  Glucose	  metabolism	  regulates	  YAP/TAZ	  transcriptional	  activity 
 
A) Luciferase assay in MDA-MB-231 breast cancer cells transfected with the 
synthetic YAP/TAZ reporter 8XGTIIC-lux. Starting on the day after DNA 
transfection, cells were treated for 24h with the indicated small-molecule 
inhibitors to block glucose metabolism (50mM  2DG; 1mM Lonidamine, Loni) or 
with an inhibitor of the mitochondrial respiratory chain (1mM Oligomycin, 
Oligo). Activity of the reporter is normalized to cotransfected CMV-lacZ, and 
expressed relative to the cells treated with vehicle only (Co.). Representative 
results of a single experiment with n=2 biological replicates; 4 independent 
experiments were consistent. 
In the case of 2DG treatment, cells were also released in fresh medium for 24h 
(fresh medium). Where indicated, cells were also transfected with YAP/TAZ (YT) 
siRNA. 2 independent experiments were consistent. 
 
B) Luciferase assay in MDA-MB-231 cells treated for 24h with 2DG and/or with 
Mannose (25mM). Representative results of a single experiment with n=2 
biological replicates; 2 independent experiments were consistent. 
 
C) Luciferase assay in MDA-MB-231 cells transfected with the CTGF-luciferase 
reporter (containing the TEAD-binding region of the natural CTGF promoter27) 
and treated for 24h with 2DG, Lonidamine. 2 independent experiments were 
consistent. Where indicated cells were also transfected with the indicated control 
(Co.) and YAP/TAZ (YT) siRNAs. 
 
D) Luciferase assay in Hs578T cells and treated with 2DG. Where indicated cells 
were also transfected with the indicated control (Co.) and YAP/TAZ (YT) 
siRNAs. Representative results of a single experiment with n=2 biological 
replicates; 2 independent experiments were consistent. 
 
E) Luciferase assay in HepG2 cells treated with 2DG or Lonidamine to inhibit 
glucose metabolism. Representative results of a single experiment with n=2 
biological replicates; 2 independent experiments were consistent. 
 
F) Luciferase assay in MDA-MB-231 transfected with the Notch-responsive 
RBPJ-lux reporter alone (Co.) or in combination with increasing doses of 
constitutively-active Notch plasmid (NΔE, bearing deletion of the extracellular 
domain) and treated with 2DG. Representative results of a single experiment with 
n=2 biological replicates; 2 independent experiments were consistent. 
 
G) Luciferase assay in MDA-MB-231 transfected with the 8XGTIIC-Rlux 
(Renilla-luciferase) or with the CMV-Rlux reporters, and treated with 2DG. 
Renilla luciferase, at difference with firefly luciferase, is not an ATP-dependent 
enzyme and therefore its activity is formally insensitive to ATP levels. 
Representative results of a single experiment with n=2 biological replicates; 2 
independent experiments were consistent. 
 
Unless indicated otherwise, error bars represent mean ± SD. * p-value<0,01 
relative to control.  
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FIGURE	  3.	  Evidence	  supporting	  a	  direct	  regulation	  of	  YAP/TAZ	  by	  glucose 
 
A) Luciferase assay in MDA-MB-231 cells transfected with an E2F-responsive 
reporter (6XE2F-lux) (top) or with the YAP/TAZ reporter (8XGTIIC) (bottom) 
and treated with 2DG. As expected, co-transfection of plasmids encoding for the 
CDK inhibitors p16, p21 and p27 inhibits E2F activity, whereas YAP/TAZ 
activity is not repressed. Representative results of a single experiment with n=2 
biological replicates; 2 independent experiments were consistent. 
 
B) Luciferase assay in MDA-MB-231 cells bearing a stably integrated TRE-
8XGTIIC-lux reporter. Before harvesting, cells were either left unstimulated (0) 
or supplemented with doxycycline to release transcription (4, 6, 8 and 10h). 
Top: cells were transfected with the indicated control (Co.) and YAP/TAZ (YT) 
siRNAs for 48h; results indicate that doxycicline-induced transcription is 
YAP/TAZ dependent. 
Bottom: 2DG (100mM) was added together with doxycycline to acutely block 
glucose metabolism. Representative results of a single experiment with n=2 
biological replicates; 3 independent experiments were consistent. 
 
C) Luciferase assay in MDA-MB-231 cells bearing a stably integrated TRE-
8XGTIIC-lux reporter. Glucose was removed from the culture medium at the 
moment of doxycycline supplementation (- Glu). Cells were harvested 24h after 
treatment. Representative results of a single experiment with n=2 biological 
replicates; 3 independent experiments were consistent. 
 
D) HepG2 cells were put in medium with (Co.) or without glucose for transfection 
of the luciferase reporter plasmid; after 36h, cells were either left for another 36h 
in absence of glucose (- Glu) or refed with glucose (+ Glu). Representative results 
of a single experiment with n=2 biological replicates; 2 independent experiments 
were consistent. 
 
E) Luciferase assay in MCF10A-MII cells bearing a stably integrated TRE-
CTGF-lux reporter. Cells were transfected with the indicated control (Co.) and 
YAP/TAZ (YT) siRNAs; after one day cells were either left unstimulated (0) or 
supplemented with doxycycline to release transcription (24h). Doxycicline-
induced transcription is YAP/TAZ dependent. Representative results of a single 
experiment with n=2 biological replicates; 3 independent experiments were 
consistent. 
 
F) Luciferase assay in MCF10A-MII cells bearing a stably integrated TRE-
CTGF-lux reporter. Cells were left unstimulated (0) or supplemented with 
doxycycline (6, 8 and 10h of treatment) to release YAP/TAZ-dependent 
transcription (Co.). 2DG (100mM) was added together with doxycycline to 
acutely inhibit glycolysis. Representative results of a single experiment with n=2 
biological replicates; 3 independent experiments were consistent. 
 
G) Luciferase assay was carried out by removing glucose from the culture 
medium (- Glu) at the moment of doxycycline supplementation. Cells were 
harvested 24h after treatment. Representative results of a single experiment with 
n=2 biological replicates; 3 independent experiments were consistent. 
	   	  
	   69	  	   	  
FIGURE"3"
A"
p<0.0001 p<0.0001 
YA
P/
TA
Z 
si
gn
at
ur
e
av
er
ag
e 
ex
pr
es
si
on
MCF10A MDA-MB-231
Control 
2DG treatment 
1.00 
0.75 
0.50 
0.25 
0 
2DG Co. 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
8XGTIIC-lux MDA-MB-231 
Loni Oligo
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
0  4  6  8 10 
Co. 2DG 
1200 
900 
600 
300 
0 
0  4  6  8 10 
2000 
1500 
1000 
500 
0 
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
Co. 
0  24  
Glu
0  24  
12 
9 
6 
3 
0 
30 
15 
10 
5 
0 
4 
3 
2 
1 
0 
AQP3 VSIG1 CYP1B1 
CDCA7 CDC25ARRM2F3 TK1
1.00 
0.75 
0.50 
0.25 
0 
HMMR 
Co. 2DG siCo siYT1 siYT2
A
C
F
D E
B
Figure 1.
ª 2015 The Authors The EMBO Journal
Elena Enzo et al Glycolysis tunes YAP/TAZ activity The EMBO Journal
3
Published online: March 21, 2015 
p<0.0001 p<0.0001 
YA
P/
TA
Z 
si
gn
at
ur
e
av
er
ag
e 
ex
pr
es
si
on
MCF10A MDA-MB-231
Control 
2DG treatment 
1.00 
0.75 
0.50 
0.25 
0 
2DG Co. 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
8XGTIIC-lux MDA-MB-231 
Loni Oligo
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
0  4  6  8 10 
Co. 2DG 
1200 
900 
600 
300 
0 
0  4  6  8 10 
2000 
1500 
1000 
500 
0 
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
Co. 
0  24  
Glu
0  24  
12 
9 
6 
3 
0 
30 
15 
10 
5 
0 
4 
3 
2 
1 
0 
AQP3 VSIG1 CYP1B1 
CDCA7 CDC25ARRM2F3 TK1
1.00 
0.75 
0.50 
0.25 
0 
HMMR 
Co. 2DG siCo siYT1 siYT2
A
C
F
D E
B
Figure 1.
ª 2015 The Authors The EMBO Journal
Elena Enzo et al Glycolysis tunes YAP/TAZ activity The EMBO Journal
3
Published online: March 21, 2015 p<0.0001 p<0.0001 
YA
P/
TA
Z 
si
gn
at
ur
e
av
er
ag
e 
ex
pr
es
si
on
MCF10A MDA-MB-231
Control 
2DG treatment 
1.00 
0.75 
0.50 
0.25 
0 
2DG Co. 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
8XGTIIC-lux MDA-MB-231 
Loni Oligo
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
0  4  6  8 10 
Co. 2DG 
1200 
900 
600 
300 
0 
0  4  6  8 10 
2000 
1500 
1000 
500 
0 
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
Co. 
0  24  
Glu
0  24  
12 
9 
6 
3 
0 
30 
15 
10 
5 
0 
4 
3 
2 
1 
0 
AQP3 VSIG1 CYP1B1 
C CA7 CDC25ARRM2F3 TK1
1.00 
0.75 
0.50 
0.25 
0 
HMMR 
Co. 2DG siCo siYT1 siYT2
A
C
F
D E
B
Figure 1.
ª 2015 The Authors The EMBO Journal
Elena Enzo et al Glycolysis tunes YAP/TAZ activity The EMBO Journal
3
Published online: March 21, 2015 
p<0.0001 p<0.0001 
YA
P/
TA
Z 
si
gn
at
ur
e
av
er
ag
e 
ex
pr
es
si
on
MCF10A MDA-MB-231
Control 
2DG treatment 
1.00 
0.75 
0.50 
0.25 
0 
2DG Co. 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
8XGTIIC-lux MDA-MB-231 
Loni Oligo
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
0  4  6  8 10 
Co. 2DG 
1200 
900 
600 
300 
0 
0  4  6  8 10 
2000 
1500 
1000 
500 
0 
 A
ct
iv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
Co. 
0  24  
Glu
0  24  
12 
9 
6 
3 
0 
30 
15 
10 
5 
0 
4 
3 
2 
1 
0 
AQP3 VSIG1 CYP1B1 
CDCA7 CDC25ARRM2F3 TK1
1.00 
0.75 
0.50 
0.25 
0 
HMMR 
Co. 2DG siCo siYT1 siYT2
A
C
F
D E
B
Figure 1.
ª 2015 The Authors The EMBO Journal
Elena Enzo et al Glycolysis tunes YAP/TAZ activity The EMBO Journal
3
Published online: March 21, 2015 
B"
siCo." siYT"#1" siYT"#2"
p<0.0001 p<0.0001 
YA
P/
TA
Z 
sig
na
tu
re
av
er
ag
e 
ex
pr
es
sio
n
MCF10A MDA-MB-231
Control 
2DG treatment 
1.00 
0.75 
0.50 
0.25 
0 
2DG Co. 
Re
la
tiv
e 
Lu
cif
er
as
e 
Ac
tiv
ity
8XGTIIC-lux MDA-MB-231 
Loni Oligo
Lu
cif
er
as
e 
Ac
tiv
ity
 (A
.U
.)
TRE-8XGTIIC-lux 
0  4  6  8 10 
Co. 2DG 
1200 
900 
600 
300 
0 
0  4  6  8 10 
2000 
1500 
1000 
500 
0 
 A
ct
ivi
ty
 (A
.U
.)
TRE-8XGTIIC-lux 
Co. 
0  24  
Glu
0  24  
12 
9 
6 
3 
0 
30 
15 
10 
5 
0 
4 
3 
2 
1 
0 
AQP3 VSIG1 CYP1B1 
CDCA7 CDC25ARRM2F3 TK1
1.00 
0.75 
0.50 
0.25 
0 
HMMR 
Co. 2DG siCo siYT1 siYT2
A
C
F
D E
B
Figure 1.
ª 2015 The Authors The EMBO Journal
Elena Enzo et al Glycolysis tunes YAP/TAZ activity The EMBO Journal
3
Published online: March 21, 2015 
C" D"
E" MCF10A-MII F" G"
	  70	  
FIGURE	  4.	  Glucose	  metabolism	  and	  YAP/TAZ	  regulate	  a	  common	  set	  of	  genes	  
important	  for	  proliferation	  
 
A) YAP/TAZ are required for transcription of 2DG-regulated genes. qPCR for 
endogenous target genes in MDA-MB-231 cells treated with water (Co.) or with 
2DG, or transfected with the indicated siRNAs: control (siCo.), YAP/TAZ mix #1 
(siYT1), YAP/TAZ mix #2 (siYT2). Expression levels were calculated relative to 
GAPDH, and are given relative to Co. cells (arbitrarily set to 1). Genes were 
selected among the probes commonly regulated in microrarray profiling. Both 
2DG-induced and 2DG-inhibited genes were coherently regulated by YAP/TAZ 
knockdown. YAP1 and TAZ levels serve as control for the efficiency of siRNA 
transfection. TXNIP is a positive control for 2DG-regulated transcription11. n=4 
biological replicates from 2 independent experiments. All differences had p-
value<0.01. 
 
B) qPCR for endogenous target genes in Hs578T breast cancer cells treated with 
water (Co.) or with 2DG, or transfected with the indicated siRNAs: control 
(siCo.), YAP/TAZ (siYT). Expression levels were calculated relative to GAPDH, 
and are given relative to Co. cells (arbitrarily set to 1). n=4 biological replicates 
from 2 independent experiments. All differences have p-value<0.01. 
 
C) Enrichment (expressed as –log10(p)) of Gene Ontology (GO) terms among the 
genes co-regulated by glucose metabolism and YAP/TAZ. 
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FIGURE	  5.	  Glycolysis	  sustains	  YAP/TAZ	  activity 
 
A) A simplified scheme indicating the main metabolic routes followed by 
glucose, the key intermediates and enzymes involved, and the inhibitors used in 
this study. DON and AZS inhibit the enzyme mediating the first step of the 
hexosamine pathway26,54,55. Colored boxes indicate three pathways fueled by 
glucose. Dashed arrows indicate downstream intermediates or metabolic 
pathways. 
 
B) Phosphoglucoisomerase (GPI) is required for YAP/TAZ activity. Luciferase 
assay in MDA-MB-231 cells transfected with the indicated siRNAs. See (C) for 
validation of siRNA efficiency. Representative results of a single experiment with 
n=2 biological replicates; 3 independent experiments were consistent. 
 
C) qPCR for endogenous mRNA levels shows efficient depletion of GPI in 
MDA-MB-231 cells 48h after siRNA transfection. n=4 biological replicates from 
2 independent experiments. 
 
D) Luciferase assay in cells treated for 24h with chemical inhibitors of the 
glucosamine-fructose-6-phosphate transaminase enzyme (GFPT), mediating the 
first committed step of the hexosamine biosynthetic pathway (HBP). DON 
(30mM) is 6-diazo-5-oxo-L-norleucine; AZS (30mM) is O-diazoacetyl-l-serine. 
Doses were as in26,54. Control cells (Co.) were treated with the same concentration 
of vehicle alone (DMSO). Representative results of a single experiment with n=2 
biological replicates; 2 independent experiments were consistent. 
 
E) Luciferase assay in MDA-MB-231 cells treated for 24h with 2DG and/or with 
GlcNAc (30mM). GlcNAc supplementation can rescue protein glycosylation in 
cells with inhibited glucose metabolism54, but is unable to rescue YAP/TAZ 
inhibition. Representative results of a single experiment with n=2 biological 
replicates; 2 independent experiments were consistent. 
 
 
  
	   73	  	   	  
800 
600 
400 
200 
0 
siGPI 
#1 
siCo. 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux MDA 
siGPI 
#2 
1.00 
0.75 
0.50 
0.25 
0 
siGPI 
#1 
siCo. 
m
R
N
A 
ex
pr
es
si
on
!
GPI MDA 
siGPI 
#2 
0!
500000!
1000000!
1500000!
2000000!
2500000!
1! 2! 3!
2000 
1500 
1000 
500 
0 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
TRE-8XGTIIC-lux MDA-MB-231 
Glu Gal Gal + Glu 
0  8  24 0  8  24 0  8  24 
2400 
1800 
1200 
600 
0 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux MDA-MB-231 
Co. 2DG 2DG Co. 
+ GlcNAc 
Figure 2 Enzo et al. 
Glucose 
G6P 
F6P 
F1,6P 
F2,6P 
Pentose 
Phosphate 
Pathway 
Pyruvate 
HK 
GPI 
PFK1 
Hexosamine 
Biosynthetic 
Pathway 
GlcNAc 
Glycosylation 
Loni. 
2DG DON, AZS 
0!
10000!
20000!
30000!
40000!
50000!
60000!
70000!
80000!
90000!
1! 2! 3!
1200 
900 
600 
300 
0 
- Glu Co. 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux HepG2 
+ Glu 
8000 
6000 
4000 
20  
 L
uc
ife
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux UOK262 
2DG Co. FH 
0 
20 
40 
1! 2!
0 
200 
400 
600 
800 
1000 
0 10 20 30 40 
ECAR (mpH/min µg) 
O
C
R
 (p
M
ol
/m
in
 µ
g)
 
MDA-MB-231 
Glu 
MDA-MB-231 
Gal 
OCR / ECAR 
A B C 
D E F 
FIGURE"5"
800 
600 
400 
200 
0 
siGPI 
#1 
siCo. 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux MDA 
siGPI 
#2 
1.00 
0.75 
0.50 
0.25 
0 
siGPI 
#1 
siCo. 
m
R
N
A 
ex
pr
es
si
on
!
GPI MDA 
siGPI 
#2 
0 
20 
40 
1! 2!
0 
200 
400 
600 
800 
1000 
0 10 20 30 40 
ECAR (mpH/min µg) 
O
C
R
 (p
M
ol
/m
in
 µ
g)
 
MDA-MB-231 
Glu 
MDA-MB-231 
Gal 
OCR / ECAR 
0!
20!
40!
60!
80!
100!
120!
1! 2! 3! 4!
1.25 
1.00 
0.75 
0.50 
0.25 
0 
DON Co. 
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
!
8XGTIIC-lux 
AZS 
1600 
1200 
800 
400 
0 
Co. 
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (A
.U
.)!
8XGTIIC-lux 
AZD2014 
P-S6 
S6 
Co. AZD!
A B 
Supplementary Figure 2 Enzo et al. 
C OCR / CAR 
A"
B" C"
D" E"
Glycolysis 
	  74	  
FIGURE	  6.	  Modulation	  of	  glycolytic	  levels	  causes	  a	  corresponding	  variation	  in	  
YAP/TAZ	  activity 
 
A) The plot indicates basal oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) of TRE-8XGTIIC-lux MDA-MB-231 cells grown in 
glucose (red, Glu) or 10mM galactose (blue, Gal). As expected, galactose induces 
a metabolic shift from aerobic glycolysis to oxidative phosphorylation compared 
to glucose. Representative results of a single experiment with n=5 biological 
replicates; 2 independent experiments were consistent. 
 
B) Representative traces of OCR (indicative of mitochondrial respiration) 
performed with an extracellular flux analyzer on monolayers of MDA-MB-231 
cells cultured in glucose (red) or in galactose (blue). Subsequent additions of the 
ATP synthase inhibitor Oligomycin (0.8mM), the uncoupler FCCP (400nM), the 
electron transport chain (ETC) complex I inhibitor Rotenone (1mM) and the ETC 
complex III inhibitor antimycin A (1mM) were carried out. Galactose-fed cells 
display enhanced respiration and respirator capacity. Representative results of a 
single experiment with n=5 biological replicates; 2 independent experiments were 
consistent. 
 
C-D) Representative traces of ECAR (indicative of aerobic glycolysis) performed 
with an extracellular flux analyzer on monolayers of MDA-MB-231 cells cultured 
in glucose (red) or in galactose (blue). In (C), subsequent additions of the ATP 
synthase inhibitor Oligomycin (0.8mM), the uncoupler FCCP (400nM), the 
electron transport chain (ETC) complex I inhibitor Rotenone (1mM) and the ETC 
complex III inhibitor antimycin A (1mM) were carried out. Galactose-fed cells 
display reduced basal and maximal glycolysis levels. In (D), cells were kept in 
sugar-free medium and subsequently supplemented with Glucose (10mM), with 
the ATP synthase inhibitor Oligomycin (0.8mM), with the glucose inhibitor 2DG 
(100mM) and with culture medium. Galactose-fed cells resume to normal or even 
higher glycolysis levels upon addition of Glucose. Representative results of a 
single experiment with n=5 biological replicates; 2 independent experiments were 
consistent. 
 
E-F) Glucose-induced activity of the stably integrated TRE-8XGTIIC-lux reporter 
in MDA-MB-231. In (E), the activity of the reporter depends on endogenous 
YAP/TAZ, as shown by siRNA transfection. 2 independent experiments were 
consistent. In (F), comparison of YAP/TAZ activity in cells grown in glucose 
(red, Glu), in galactose to induce a shift toward oxidative respiration (blue, Gal), 
or shifted back to glucose during doxycycline treatment (blue bars with red 
stripes, Gal + Glu). Cells were treated with doxycycline to release YAP/TAZ-
dependent luciferase transcription for 8 or 24h. Galactose-fed cells display 
reduced glycolysis and downregulate YAP/TAZ activity. Glucose rapidly 
reactivates glycolysis (D) and YAP/TAZ activity (Gal + Glu). 3 independent 
experiments were consistent. 
 
G) Luciferase assay in UOK262 kidney cancer cells, bearing mutation of the 
fumarate hydratase (FH) enzyme of the TCA cycle. FH-reconstituted cells (gray 
bars) display a reduction of aerobic glycolysis and increased respiration59. 2DG 
treatment (12mM) of parental cells serves as a positive control for inhibition of 
the glycolysis-YAP/TAZ axis. 2 independent experiments were consistent.  
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toward oxidative phosphorylation (Bustamante & Pedersen, 1977;
Rossignol, 2004; Marroquin et al, 2007; Chang et al, 2013). In line,
we observed a strong reduction of glycolysis and an increase in respi-
ration in MDA-MB-231 cells grown in galactose (Fig 2C; Supplemen-
tary Fig S2D–F). Strikingly, cells with reduced glycolysis displayed a
corresponding reduction of YAP/TAZ activity (Fig 2D); moreover, this
was restored when we added back glucose during the last part of the
experiment only (Fig 2D; Supplementary Fig S2G), in line with a
rapid response of YAP/TAZ to glucose shown before. A downregula-
tion of YAP/TAZ activity was also observed in UOK262 cells upon
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Figure 2. Glycolysis sustains YAP/TAZ activity.
A A simplified scheme indicating the main metabolic routes followed by glucose, the key intermediates and enzymes involved, and the inhibitors used in this study.
Only the pathways and enzymes discussed in the text are shown here for simplicity. G6P: glucose-6-phosphate; F6P: fructose-6-phosphate; F1,6P: fructose-1,6-
bisphosphate; F2,6P: fructose-2,6-bisphosphate; GlcNAc: N-acetyl glucosamine; HK: hexokinase; GPI: phosphoglucoisomerase; PFK1: 6-phosphofructo-1-kinase; PFKFB3:
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3. Lonidamine (Loni.) inhibits HK (Tennant et al, 2010); 2DG inhibits both HK and GPI (Wick et al, 1957;
Tennant et al, 2010); DON and AZS inhibit the enzyme mediating the first step of the hexosamine pathway (Wellen et al, 2010; Ostrowski & van Aalten, 2013;
Onodera et al, 2014). The green arrow indicates the agonistic effect of F2,6P on PFK1. Dashed arrows indicate downstream intermediates or metabolic pathways.
B Phosphoglucoisomerase (GPI) is required for YAP/TAZ activity. Luciferase assay in MDA-MB-231 cells transfected with the indicated siRNAs. See Supplementary Fig S2A
for validation of siRNA efficiency. Representative results of a single experiment with n = 2 biological replicates; three independent experiments were consistent.
C The plot indicates basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of TRE-8XGTIIC-lux MDA-MB-231 cells grown in glucose (red, Glu)
or 10 mM galactose (blue, Gal). As expected, galactose induces a metabolic shift from aerobic glycolysis to oxidative phosphorylation compared to glucose. See
Supplementary Fig S2D–F for detailed OCR and ECAR traces. Representative results of a single experiment with n = 5 biological replicates; two independent
experiments were consistent.
D Comparison of YAP/TAZ activity in MDA-MB-231 cells bearing a stably integrated TRE-8XGTIIC-lux reporter and grown in glucose (red, Glu), in galactose to induce a
shift toward oxidative respiration (blue, Gal), or shifted back to glucose during doxycycline treatment (blue bars with red stripes, Gal + Glu). Cells were treated with
doxycycline to release YAP/TAZ-dependent luciferase transcription for 8 or 24 h. Galactose-fed cells display reduced glycolysis and downregulate YAP/TAZ activity.
Glucose rapidly reactivates glycolysis (Supplementary Fig S2F) and YAP/TAZ activity (Gal + Glu). Representative results of a single experiment with n = 2 biological
replicates; three independent experiments were consistent.
E Luciferase assay in UOK262 kidney cancer cells, bearing mutation of the fumarate hydratase (FH) enzyme of the tricarboxylic acid cycle (TCA). FH-reconstituted cells
(gray bars) display a reduction of aerobic glycolysis and increased respiration (Yang et al, 2013). 2DG treatment (12 mM) of parental cells serves as a positive control
for inhibition of the glycolysis–YAP/TAZ axis in parental cells. Representative results of a single experiment with n = 2 biological replicates; two independent
experiments were consistent.
Data information: Throughout the figure, error bars represent mean ! SD. *P-value < 0.01.
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FIGURE	  7.	  YAP/TAZ	  regulation	  by	  glucose	  metabolism	  does	  not	  involve	  
known	  YAP/TAZ	  regulators	  or	  energy-­‐sensing	  pathways 
 
A) Hippo signaling is not involved in regulation of YAP/TAZ by 2DG. Luciferase 
assay in cells transfected with control (siCo.) or with an established LATS1/2 
siRNA mix (siLATS1/2)32, and then either treated with 2DG (black bars) or 
transfected with NF2 expression plasmid to specifically activate the Hippo 
pathway (green bars). Depletion of LATS1/2 blocked the inhibitory effect of 
overexpressed NF2, but not of 2DG. Representative results of a single experiment 
with n=2 biological replicates; 2 independent experiments were consistent. 
 
B) Mevalonate metabolism is not involved in regulation of YAP/TAZ by 2DG. 
Cells were transfected with the 8XGTIIC-lux YAP/TAZ reporter and treated with 
2DG (black bars) or with Cerivastatin (3mM, red bars), an inhibitor of the 
mevalonate pathway at the level of HMG-CoA reductase. Adding back 
mevalonate in the culture medium (+ mevalonate, 1mM) rescues YAP/TAZ 
inhibition from Cerivastatin, but not from 2DG. Representative results of a single 
experiment with n=2 biological replicates; 2 independent experiments were 
consistent. 
 
C) Representative confocal immunofluorescence images of YAP/TAZ and nuclei 
(hoechst) in MDA-MB-231 cells. Cells were treated for 24h with 2DG (100mM) 
or with Cerivastatin (3µM), as positive control of nuclear exclusion. 
Bottom: Quantification of cells shows predominantly nuclear (N), even (N/C) or 
predominantly cytoplasmic (C) YAP/TAZ subcellular localization. Scale bar: 
15µm. n>250 cells were observed for each condition. 
 
D) MDA-MB-231 cells were transfected with the 8XGTIIC-lux reporter and 
treated for 24h with increasing doses (0.1 - 0.3 - 1mM) of the dual mTORC1/2 
inhibitor AZD2014. Representative results of a single experiment with n=2 
biological replicates; 2 independent experiments were consistent.  
On the right: Western blotting of MDA-MB-231 cell extracts treated with DMSO 
(Co.) or treated for 24h with AZD2014 (0.1mM; AZD) and probed for 
phosphorylated-S6 (an established read-out of mTOR inhibition) and total S6 
ribosomal protein 
 
E) AMPK, key energy sensor activated upon nutrient starvation, is not involved in 
regulation of YAP/TAZ by 2DG. Luciferase assay in MDA-MB-231 cells treated 
for 24h with 2DG (black bars) and/or with Compound-C (30mM), an established 
inhibitor of AMPK. Representative results of a single experiment with n=2 
biological replicates; 3 independent experiments were consistent. 
On the right: Western blotting of MDA-MB-231 cell extracts treated for 24 h with 
2DG (black bars) and/or with Compound-C (30mM) and then probed for 
phosphorylated-S6 (a read-out of AMPK activation / mTOR inhibition) and total 
S6 ribosomal protein. 
 
F) Luciferase assay in MDA-MB-231 cells transfected with AMPKa1/2 siRNAs 
and treated with 2DG. 2 independent experiments were consistent. 
On the right: Western blotting of cell extracts used for luciferase assay, validating 
AMPKa1/2 siRNAs. 
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FIGURE	  8.	  Phosphofructokinase	  regulates	  YAP/TAZ	  transcriptional	  activity 
 
A) Proteomic analysis of YAP binding partners reveals interaction with 
phosphofructokinase (PFK1). Flag-tagged YAP-5SA stably expressed in 
MCF10A and MDA-MB-231 cells was immunoprecipitated, and associated 
proteins identified using mass spectrometry. 
Left panel: silver staining of the purified proteins in representative control (Co.) 
or YAP immunopurifications. Molecular weight markers are indicated. The 
asterisk indicates the band corresponding to YAP. 
Right scheme: The thickness of the lines connecting YAP to its partners is 
proportional to the number of peptides isolated for each partner. Black proteins 
(known YAP partners) and PFK1 (in red) were isolated in both cell lines; grey 
proteins are known regulators of YAP that were only purified from MCF10A 
cells. 
 
B) Western blotting of MDA-MB-231 cells transfected with the indicated siRNAs 
and probed with different antibodies detecting endogenous levels of PFK1. 
 
C) Luciferase assay in MDA-MB-231 cells transfected with control (siCo.) or two 
independent PFK1 siRNAs (siPFK1 #1, #2). Representative results of a single 
experiment with n=2 biological replicates; 4 independent experiments were 
consistent.  
 
D) Luciferase assay in MDA-MB-231 cells transfected with the CTGF-lux 
reporter and with the indicated control (Co.) and PFK1 (P) siRNAs. 2 independent 
experiments were consistent. 
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FIGURE	  9.	  Phosphofructokinase	  directly	  interacts	  with	  TEADs 
 
A) In vitro pull-down assay with purified FLAG-PFK1 and recombinant GST-
YAP. GST-YAP was incubated with (first lane) or without (second lane) FLAG-
PFK1; as positive control, GST-YAP was incubated with purified FLAG-TEAD1 
(right-most lane). Proteins were then subjected to anti-FLAG 
immunoprecipitation, and purified complexes were probed for coprecipitation of 
GST-YAP (anti-YAP immunoblot).  
 
B) In vitro pull-down assay with purified FLAG-PFK1 and recombinant GST-
TEAD4. GST-TEAD4 was incubated with (first lane) or without (second lane) 
FLAG-PFK1. Proteins were then subjected to anti-FLAG immunoprecipitation, 
and purified complexes were probed for coprecipitation of GST-TEAD4 (anti-
TEAD4 immunoblot). 
 
C) Lysates from HEK293 cells transfected with the indicated proteins were 
subjected to anti-FLAG-PFK1 immunoprecipitation, and purified complexes were 
probed for coprecipitation of MYC-TEAD4. Mutation of a key aminoacid 
required for interaction between TEAD4 and YAP/TAZ (Y429H) did not interfere 
with PFK1 interaction. 
 
D) MDA-MB-231 cell lysates were immunoprecipitated with anti-TEAD1 
antibody, and the precipitating proteins were probed for TEAD1 or PFK1. 
Immunoprecipitation with an unrelated IgG serves as negative control. 
 
E) Red: Immunofluorescence for endogenous PFK1 with two different primary 
antibodies in MDA-MB-231 cells. Blue: DAPI serves as nuclear counterstain. 
 
F) Representative confocal images of MCF10A-MII cells subjected to proximity-
ligation assay (PLA, in red) by using anti-PFK1 and anti-TEAD1 antibodies. In 
this assay, two proteins are detected in situ with primary antibodies, and the 
secondary antibodies are conjugated to DNA oligonucleotides instead of 
fluorophores. Slides are then subjected to DNA ligation and DNA polymerization 
in the presence of fluorescent-labeled nucleotides: only when the proteins are 
close to each other the enzymatic reaction takes place, producing discrete sub-
nanometer fluorescent dots. Specificity of the assay in detecting nuclear 
PFK1/TEAD1 proximity was assessed by removing anti-PFK1 or anti-TEAD1 
primary antibodies.  DAPI serves as a nuclear counterstain. Yellow dashed lines 
indicate the position of one nucleus in each PLA image.  Scale bar: 15µm. 
 
G) Luciferase assay in HEK293 cells transfected with 8XGTIIC-lux reporter and 
with increasing doses of PFKFB3 expression plasmid. PFKFB3 converts F6P into 
F2,6BP, a potent allosteric activator of PFK1134, suggesting that increased PFK1 
activity fosters YAP/TAZ activity. 3 independent experiments were consistent. 
 
H) Mutation of the F2,6BP allosteric site of PFK1 negatively regulates its 
interaction with TEAD4. HEK293 cells were transfected with MYC-TEAD4 and 
increasing doses of wild-type (WT) or mutated (F2,6P mut) Flag-PFK1 plasmids; 
cell extracts were immunoprecipitated with anti-FLAG and the coprecipitating 
MYC-TEAD4 protein was detected by western blotting. Immunoprecipitation in 
the absence of FLAG-PFK1 (lane 1) serves as a negative control. Quantifications 
of the TEAD4/PFK1 ratio are provided, relative to lane 2. 
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FIGURE	  10.	  Glucose	  metabolism	  regulates	  the	  interaction	  between	  YAP/TAZ	  
and	  TEADs 
 
A) Glucose metabolism is required for efficient interaction between endogenous 
YAP and TEAD1 proteins. Extracts of MDA-MB-231 cells treated for 24h with 
vehicle (-) or with 2DG (+) were subjected to anti-YAP immunoprecipitation; 
coprecipitating proteins were then analyzed by western blotting to detect TEAD1 
interaction. Immunoprecipitation with an unrelated IgG serves as negative control. 
 
B) Same as in (A), but YAP/TAZ were immunoprecipitated with a different 
antibody (anti-TAZ). Immunoprecipitation with an unrelated IgG (lane 1) serves 
as negative control. 
 
C-D) Co-immunoprecipitation of endogenous YAP and TEAD1 proteins from 
extracts of MCF10A (C) or HepG2 (D) cells untreated (-) or treated (+) with 2DG 
for 24h. Immunoprecipitation with IgG (lane 1) serves as negative control. 
 
E) Co-immunoprecipitation of endogenous YAP and TEAD1 proteins from 
extracts of UOK262 cells untreated (-), treated with 2DG (15mM) or with 
Verteporfin (VP, 30mm) for 24h. VP serves as positive control for inhibition of 
YAP/TEAD1 complexes. Immunoprecipitation with an unrelated IgG (lane 1) 
serves as negative control. 
 
F) Glucose regulates endogenous YAP/TEAD1 interaction. Co-
immunoprecipitations from extracts of MCF10A cells released from contact 
inhibition by seeding them at low confluence for 36h with glucose (+, lane 2), 
without glucose (-, lane 3), or cultured without glucose and then refed of glucose 
(+, lane 4). Immunoprecipitation with IgG (lane 1) serves as negative control. 
 
G) Co-immunoprecipitation of endogenous YAP and TEAD1 proteins from 
extracts of HepG2 cells cultured for 36h with glucose (+, lane 2), without glucose 
(-, lane 3), or cultured without glucose and then refed of glucose (+, lane 4). 
Immunoprecipitation with an unrelated IgG (lane 1) serves as negative control. 
 
H) Representative confocal immunofluorescence images of TEAD1 (green) and 
nuclei (Hoechst - blue) in MDA-MB-231 cells. Cells were treated for 24h with 
100mM 2DG. Hoechst is a nuclear counterstain. Scale bar: 15µm. n>200 cells. 
 
I) Immunoprecipitation of YAP and TEAD1 is reinforced upon glucose 
supplementation (+), and this requires endogenous PFK1 levels. 
 
J) In situ interaction of YAP and TEAD1 is regulated by PFK1 by Proximity 
Ligation Assay (PLA). Depletion of YAP/TAZ (siYT) or PFK1 with two 
independent siRNAs (siPFK1 #1, #2) in MCF10A cells reduced the number of 
nuclear YAP/TEAD1 dots relative to cells transfected with control siRNA (siCo.), 
suggesting PFK1 is required to stabilize YAP/TEAD1 interaction. 
On the left: Representative pictures of MCF10A cells subjected to PLA by using 
anti-YAP and anti-TEAD1 antibodies. Specificity of the assay in detecting 
endogenous YAP/TEAD1 proximity was assessed by the expected nuclear 
localization of the PLA red dots (bottom pictures) and by removing anti-YAP 
primary antibody (top pictures showing background/aspecific dots). DAPI serves 
as a nuclear counterstain. Scale bars 15mm. 
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FIGURE	  11.	  Glucose	  metabolism	  regulates	  the	  stability	  of	  YAP/TEAD	  
transcriptional	  complexes 
 
A-B) Chromatin immunoprecipitation of MCF10A (A) and MDA-MB-231 (B) 
cells untreated (Co.) or treated with 100mM 2DG for 24h. Fragmented chromatin 
from each experimental condition was immunoprecipitated with control IgG or 
anti-YAP antibodies, and subjected to qPCR to detect the TEAD-binding regions 
present in the CTGF, ANKRD1, HMMR and TK1 promoters. Amplification of 
Hemoglobin beta (HBB) serves as negative control. Values in Control samples 
with control IgG were arbitrarily set to 1 and the other values are relative to this. 
Data are shown as the mean ± SD of two independent experiments. 
 
C-D) Luciferase assays in MDA-MB-231 cells transfected with the TK1-
luciferase reporter. By visual inspection, we identified two conserved TEAD-
binding motifs in the proximal promoter region of the TK1 gene; this promoter 
region, when cloned upstream of a luciferase reporter, drives transcription in a 
manner that is dependent on YAP/TAZ activity (C) and also on glycolysis (D). 
 
 
E) Luciferase assay in MDA-MB-231 cells transfected with UAS-lux reporter and 
expression plasmids encoding for in-frame fusions of the GAL4 DNA-binding 
domain with TEAD1, wild-type (WT) or unable to interact with YAP (Y406A 
mutant). In this assay, GAL4 provides the DNA-binding platform, while TEAD1 
provides transcriptional activation. WT TEAD1 can recruit YAP/TAZ and 
efficiently promote transcription, while Y406A TEAD1 can only sustain basal 
transcription78. Treatment with 2DG (black bars) inhibited transcription induced 
by WT TEAD1 but not of the Y406A mutant, in keeping with the observation that 
2DG regulates YAP/TEAD1 interaction. LatrunculinA treatment (Lat.A) serves as 
positive control for inhibition of YAP/TAZ. Representative results of a single 
experiment with n=2 biological replicates; 2 independent experiments were 
consistent. 
 
F) Luciferase assay in HEK293 cells transfected as in (E). Co-transfection of 
PFKFB3, an activator of PFK1 activity, fosters the activity of TEAD1 only when 
it is able to interact with YAP. Representative results of a single experiment with 
n=2 biological replicates; 2 independent experiments were consistent. 
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Neto-Silva et al, 2010; Ziosi et al, 2010) (Fig 5F; Supplementary Fig
S5E–G). This indicates that phosphofructokinase regulates and is
instrumental for Yki activity during tumorigenesis of fly larval
tissues.
To further extend the functional connections between glucose
metabolism and YAP/TAZ, we tested whether proliferation
promoted by glucose would depend, at least to some extent, on
YAP/TAZ. In control MDA-MB-231 cells, glucose deprivation for
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Neto-Silva et al, 2010; Ziosi et al, 2010) (Fig 5F; Supplementary Fig
S5E–G). This indicates that phosphofructokinase regulates and is
instrumental for Yki activity during tumorigenesis of fly larval
tissues.
To further extend the functional connections between glucose
metabolism and YAP/TAZ, we tested whether proliferation
promoted by glucose would depend, at least to some extent, on
YAP/TAZ. In control MDA-MB-231 cells, glucose deprivation for
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FIGURE	  12.	  Interplay	  of	  glycolysis,	  PFK1	  and	  YAP/TAZ	  in	  cancer	  cell	  growth	   	  
A-D) Mammosphere assay with MCF10A-MII cells. In (A), retroviral expression 
of an activated form of TAZ (S89A mutant) increases the efficiency of primary 
mammosphere formation compared to parental cells (empty-vector infected cells). 
Treatment of TAZ-expressing cells with 2DG (15mM), depletion of PFK1 (siP) or 
GPI (siG), impairs the mammosphere-promoting ability of TAZ. n=4 biological 
replicates; 2 independent experiments were consistent. In (B), representative 
pictures of S89A-TAZ-expressing mammospheres quantified in (A). In (C), 
primary mammospheres obtained by seeding parental MCF10A-MII cells 
transfected with siRNAs for PFK1 (P), GPI (G) or YAP/TAZ (YT). In (D), 
secondary mammospheres obtained by re-seeding mammospheres obtained from 
MCF10A-MII-TAZ S89A cells treated with 2DG as (A) or transfected with 
siRNAs for PFK1 (P) or GPI (G). 
 
E) Depletion of PFK1 (siP) impairs the colony-forming ability of MDA-MB-231 
cells in soft agar, recapitulating the requirement for YAP/TAZ (siYT). n=2 
biological replicates; 2 independent experiments were consistent. 
 
F) Expression of an activated form of YAP (5SA) strongly promotes the growth 
of MDA-MB-231 colonies in soft agar, and this is inhibited by 2DG treatment 
(3mM). Each box signifies the upper and lower quartiles of data (colony size), 
while the whiskers extend to the minimum and maximum data points. 
On the right: representative pictures of colonies. n=2 biological replicates; 4 
independent experiments were consistent. 
 
G-H) MCF10A cells were seeded at high density for 48h, leading to YAP/TAZ 
inhibition and growth arrest (High); scratching the monolayer locally enables cell 
spreading and activates YAP/TAZ, thus inducing cell proliferation (Wound)32,80. 
Overnight treatment of cells with 2DG (15mM) inhibited such YAP/TAZ-induced 
proliferation. In (G), the graph reports the quantification of proliferating cells, 
without or with 2DG. To count cells, we arbitrarily set a 100mm distance from the 
wound. n=2 biological replicates (>700 cells/replicate); 3 independent 
experiments were consistent. In (H), representative BrdU stainings and nuclear 
counterstains (DAPI) of MCF10A cell monolayers in the area abutting the wound. 
 
I) MDA-MB-231 cells were growth-inhibited by glucose withdrawal for 48h (- 
Glu), and then proliferation was induced by supplementing glucose in the medium 
for 24h (+ Glu). Culture medium was without glutamine to specifically measure 
glucose-dependent growth. Quantification of proliferation (by BrdU 
incorporation), indicates that cells depleted of YAP/TAZ (siYT #1) are unable to 
efficiently restart proliferation in response to glucose. n=2 biological replicates 
(>1000 cells/replicate); 3 independent experiments were consistent. 
 
J-K) Clonogenic assay with UOK262 cells. Parental cells (black bars) are highly 
glycolytic, while their FH-reconstituted counterpart (grey bars) have reduced 
glycolysis as they can efficiently perform mitochondrial respiration59. Cells were 
grown with titrated doses of 2DG (0.25, 0.5, 1mM) to inhibit glucose metabolism 
(J), or with VP (0.3, 1, 3 mM) to inhibit the cooperation between YAP/TAZ and 
TEADs41 (K). Quantification of colonies after 10 days, relative to untreated cells. 
n=3 biological replicates; 2 independent experiments were consistent. 
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FIGURE"12"
We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 primary
mammary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first derived a gene expression signature experimentally
associated wit high glucose metabolism in cells of ma mary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
micro rrays (see Materials and Methods and Supplementary Table
S5). We then nalyzed large met dataset collectin gene expres-
sion and associated clinical data of more than 3,600 primary
a mary tumors (Corde onsi et al, 2011; Montagner et al, 2012)
and evaluated how th l vels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established g ne signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Corde onsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signatur expression l vels associated
to higher expression of ma mary stem cell signatures (Liu et al,
2007; P c et al, 2 10), and it was significantly levated in G3
versus G1 grade tumors (P < . 001). Remarkably, by univariate
Kaplan–Meier sur ival nalysis, we also found that tumors
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We first derived a gene expres ion signature experimentally
as ociated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (se Materials and Methods and Su lementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and as ociated clinical data of more than 3,6 primary
ma mary tumors (Cordenonsi et al, 20 ; Montagner et al, 2012)
and evaluated how the levels of glucose signature were as ociated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is posit vely and strongly correlated with expres ion of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Su lementary Fig S6A); moreover, tumors clas ified
ac ording to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Su lementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature cor elates with cancer features previously as ociated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 20 ; Chen et al, 2012). As shown in Fig 6C–E,
we inde d found that glucose signature expres ion levels as ociated
to higher expres ion of mammary stem cell signatures (Liu et al,
2 7; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0. 1). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 primary
mammary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of ma mary
origin (glucose signature) by s lecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Su plementary Table
S5). We then analyzed a large metad taset collecting gene expres-
sion and associated cl nical d ta of more than 3,6 0 primary
ma mary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ act vity. Str kingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Su plementary Fig S6A); moreover, tumors cla sified
a cording to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Su plementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously a sociated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 20 1; Chen et al, 2012). As shown in Fig 6C–E,
we ind ed found that glucose signature expre sion levels a sociated
to higher expre sion of mammary stem cell signatures (Liu et al,
2 07; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0. 01). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first d rived a ge e expression signatur experimentally
associated with high glucose metabo ism in cells of m mmary
rigin (glucose signature) by s l cting t e g nes that w re downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplem ntary T ble
S5). We then an lyzed l rge metadataset coll cting gene expres-
sion an asso iate clinical data of more than 3,600 prima y
a mary tum rs (Cordenonsi et al, 2011; Montagner et al, 2012)
an evaluated how the evels of gl cose sign ture w re ass ciated
with YAP/TAZ activit . Strikingly, we found that the glucose
signatur is positively and st ongly correlated with expression of
previou ly established gen sig atures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); more ver, tumors classified
according to high (vers s low) gl cose ignature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this obs rvation, e tested whether the glucose
signature correl tes with cancer f at res previously associated to
YAP/TAZ a tivity, such s tumor grade a d the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that gl cos signature expre si n lev ls associated
to higher expression of ma mary tem c ll signatures (Liu et al,
2007; Pece et l, 2010), and it w s signific ntly elevated in G3
ve sus G1 g ade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysi , we also fo nd that tumors
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G"
We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 primary
mammary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how t e lev ls of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and i was gnific n ly elev ted i G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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FIGURE	  13.	  PFK1	  is	  required	  for	  Yki-­‐induced	  growth	  in	  Drosophila	  
 
A) Clonal expansion induced by overexpression of the YAP homologue Yki in 
the Drosophila wing imaginal disc is restricted by phosphofructokinase (Pfk) 
RNAi. Panels on the left show pictures of wing imaginal discs bearing clones of 
cells (marked by GFP) with mutation of the lethal giant larvae tumor suppressor 
gene (lgl-) and overexpression of Yki (ykiover), induced by the MARCM 
technique135. The dotted line indicates the outline of the discs. In this genetic 
setup, the survival of clones within the wing pouch, i.e. in the distal region of the 
wing disc, is strictly dependent on Yki activation81–83. Upon downregulation of 
phosphofructokinase, the growth of lgl-; ykiover clones was inhibited, as shown by 
quantification of clone area (P<0.0001, unpaired t-test). In order to obtain 
consistent observations, only clones included in the wing pouch region were 
considered for statistical analysis. n=34 discs for each genotype. Scale bars 
80mm. 
 
B) Pfk silencing downregulates the Yki target gene DIAP1 in lgl-; ykiover clones. 
Panels show whole mount immunostainings for DIAP1 protein levels, a hallmark 
of Yki transcriptional activity85, on wing imaginal discs of the indicated 
phenotypes, as in A. GFP identifies mutant cells, growing within an otherwise 
wild-type tissue. DIAP1 is autonomously upregulated in lgl-; ykiover clones, while 
it appears downregulated upon Pfk RNAi. This is consistent with a role for Pfk in 
regulating Yki transcriptional activity. See (D) for similar results obtained with 
dMyc, another target of Yki87,88. Scale bars 20mm. 
 
C) Low magnification pictures of whole wing imaginal discs bearing lgl-; ykiover 
or lgl-; ykiover Pfk-RNAi clones (marked by GFP) and stained for DIAP1 protein. 
The squares indicate the regions highlighted in (B). Scale bars 80mm. 
 
D) Pfk silencing in lgl-; ykiover cells attenuates dMyc expression in the wing pouch 
region. Panels show immunostainings for dMyc protein levels, an established 
target of Yki in the context of clonal expansion87,88. GFP identifies mutant cells, 
growing within an otherwise wild-type tissue. dMyc protein levels are high in lgl-; 
ykiover clones, and they appear normalized upon phosphofructokinase knockdown 
(Pfk-RNAi). Pictures were taken in the wing pouch region as in (A-B). The dotted 
line in the lower right panel indicates the borders of the clone, based on GFP 
signal. Scale bars 20mm. 
 
E) Low magnification pictures of whole wing imaginal discs bearing lgl-; ykiover or 
lgl-; ykiover Pfk-RNAi clones (marked by GFP) and stained for dMyc protein. The 
squares indicate the regions highlighted in D. Scale bars 80mm. 
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We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 primary
mammary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 primary
mammary tumors (Cordenonsi et al, 2011; Montagner et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen et al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
Kaplan–Meier survival analysis, we also found that tumors
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We first derived a gene expression signature experimentally
associated with high glucose metabolism in cells of mammary
origin (glucose signature) by selecting the genes that were downreg-
ulated by 2DG treatment both in MCF10A and in MDA-MB-231
microarrays (see Materials and Methods and Supplementary Table
S5). We then analyzed a large metadataset collecting gene expres-
sion and associated clinical data of more than 3,600 prim ry
mammary tumors (Cordenonsi et al, 2011; Montagn r et al, 2012)
and evaluated how the levels of glucose signature were associated
with YAP/TAZ activity. Strikingly, we found that the glucose
signature is positively and strongly correlated with expression of
previously established gene signatures denoting YAP/YAZ activity
(Fig 6A; Supplementary Fig S6A); moreover, tumors classified
according to high (versus low) glucose signature also display higher
activity of YAP/TAZ (Fig 6B; Supplementary Fig S6B).
Prompted by this observation, we tested whether the glucose
signature correlates with cancer features previously associated to
YAP/TAZ activity, such as tumor grade and the content of CSC
(Cordenonsi et al, 2011; Chen t al, 2012). As shown in Fig 6C–E,
we indeed found that glucose signature expression levels associated
to higher expression of mammary stem cell signatures (Liu et al,
2007; Pece et al, 2010), and it was significantly elevated in G3
versus G1 grade tumors (P < 0.0001). Remarkably, by univariate
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FIGURE	  14.	  YAP/TAZ	  activity	  is	  enhanced	  in	  primary	  human	  breast	  cancers	  
displaying	  high	  levels	  of	  a	  gene	  signature	  regulated	  by	  glucose	  
 
A-B) Scatter plot (gray dots) and linear regression (red line, slope 0.532) of 
standardized expression values indicates a positive correlation between a gene 
signature experimentally associated with active glucose metabolism (Glucose 
signature) and the “YAP/TAZ” (A) or “induced by YAP” (B) gene signature in a 
metadataset collecting n=3661 primary human breast cancers. The Glucose 
signature is composed of the genes downregulated upon 2DG treatment, i.e. 
requiring active glucose metabolism for their transcription, both in MCF10A and 
in MDA-MB-231 cells. Pearson r quantifies the linear dependence between the 
levels of the two signatures. In A: the coefficient of determination is r2=0.731, p-
value<0.0001. In B: r2=0.477, p-value<0.0001. 
 
C-D) Primary human breast cancers of the metadataset were stratified according 
to high or low Glucose signature score, and then the levels of the “YAP/TAZ” (C) 
or “induced by YAP” (D) gene signature score were determined in the two 
groups. YAP/TAZ activity is significantly higher in tumors with high levels of the 
Glucose signature, as visualized by box-plot. The bottom and top of the box are 
the first and third quartiles, and the band inside the box is the median; whiskers 
represent 1st and 99th percentiles; values lower and greater are shown as circles 
(p<0.0001, n=3661). 
 
E-F) Primary human breast cancers of the metadataset were classified according 
to high or low Glucose signature score, and then the levels of the Staminal or 
Stem tumorigenic signature scores, associated to normal and cancer mammary 
stem cells, were determined in the two groups. Gene expression associated to 
mammary stem cells is significantly higher in tumors with high levels of the 
Glucose signature, as visualized by box-plot (p<0.0001, n=3661). 
 
G) Genes regulated by glucose metabolism (Glucose signature) are elevated in G3 
as compared to G1 grade mammary tumors of the metadataset (p<0.0001; G1 vs. 
G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ 
signature45. Data are shown as mean ± standard error of the mean (SEM). 
 
H) Kaplan-Meier analysis representing the probability of metastasis-free survival 
in breast cancer patients from the metadataset stratified according to high or low 
Glucose signature score. The log-rank test p value reflects the significance of the 
association between high levels of the glucose signature score and shorter 
survival. A similar behavior is observed by using the YAP/TAZ signature45. 
 
I) Genes regulated by glucose metabolism but not by YAP/TAZ (Glucose NOT 
YT signature) are not expressed at higher levels in G3 grade mammary tumors of 
the metadataset. Data are shown as mean ± standard error of the mean (SEM). 
 
J) Kaplan-Meier analysis in breast cancer patients from the metadataset stratified 
according to high or low Glucose NOT YT signature score, which show no 
differences. 
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experimentally associated with active glucose metabolism (glucose signature) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active glucose metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
dependence between the levels of the two signatures. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels of the glucose signature, as visualized by box-plot. The bottom and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experimentally associated with active glucose metabolism (glucose signature) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active glucose metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
dependence between the levels of the two signatures. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels of the glucose signature, as visualized by box-plot. The bottom and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of stand rdized expressi n v lues indic te a posi ive correlatio betwe n a gene signatur
experimentally associated with active glucose metabolism (glucose signature) nd a gene ignature denoting YAP/TAZ act vity, in a metadatas collecting
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signatur is composed f the genes downregulated upo 2DG tr atment, that is,
requiring active glucose metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
dependence between the levels of the two signatures. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels of the glucose signature, as visualized by box-plot. The bottom and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experime tally associated with active glucose metabolism (glucose signature) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active glucose metabolism for thei transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
dependen e between he levels of the two signatures. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
high r in tumors with high levels of the glucose signature, as visualized by box-plot. The bottom and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast c ncers displaying high levels of a gene signatu e associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation betwe n a gene signature
experimentally associated with active glucose metabolism (glucose signature) and a gene signature denoting YAP/TAZ activity, in a metadata et collec ing
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active glucose metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q qua tifies the linear
dependence between the levels of the two signatures. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels of the glucose signature, as visualized by box-plot. The bottom and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated o gl colysi .
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experimentally associated with active glucose metabolism (glucose gnature) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active glucose metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
d pendence between the levels of the two signatur s. The coefficient of determination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
core were determined i the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels of the glucose signat re, s visualized by box-plot. The botto and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free surviv l in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experimentally associated with active glucose metabolism (glucose signature) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (s e Materials and Me hods). The glucose sig ature is compos d of the genes downregulated upon 2DG treatment, that is,
requiring active gluc se metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (se Supplementary Table S5). Pearson q quantifies the linear
dependence between the levels of the two signatures. The coefficient of d termination is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset wer stratified accordi g to high or low gluc se sign ture scor , a d then, the levels of the YAP/TAZ signature
score were d termi ed in th two groups (see Materials a d Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors wi high levels of the glucose signature, as visualiz d by box-plo . Th bott m and top of the box are the first and third quartiles, and the band
inside the box is the median; whiskers repr sen 1st nd 99th percentiles; values lower and greater are hown as circles (P < 0.0001, n = 3,661).
C, D Prima y human breast can ers of the metadataset were cl sified according to high or low glucose signature score, then, the levels of the Staminal or stem
tumorige ic signatur scores, ssociated to ormal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared t G1 grade mam ary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired t-test). A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data are shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ signature (Cordenonsi et al, 2011).
G Genes regulated by glucose metabolism but not by YAP/TAZ (glucose NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ ctivity is enhanced in prim ry human breast cancers displaying high levels of a gene signature ass ciated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experim ntally associated with ac ive glucose metabolism (glucose si nature) nd a gene si nature denoting YAP/TAZ ctivity, in a metadataset collecting
n = 3,661 primary human br ast cancers (see Materials and Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
req iring active glucose metabolism for their transcription, both i CF10A and in MDA-MB-231 cells (see Supplement ry Table S5). Pearson q quantifies the linear
d p denc between the levels of the two signatures. The c efficient f determi ation is r2 = 0.731, P-value < 0.0001.
B Prim ry human breast cancers of the metadataset were stratified according to high or low glu se sign ture score, and then, the levels of the YAP/TAZ signature
score were d t rmi ed i th two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in t mors wit high levels o th gluco e signature, a visualiz d by b x-plot. The bottom nd top of the box are the first and third qu rtiles, and the band
inside the b x is the median; whi kers represent 1st and 99th percentiles; values lower and greater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human reast cancers f the metadatase were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to nor al and ancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
tem cells is significantly higher in tumors with high levels of the glucos signatur , as visu ized by box-plot (P < 0.0001, n = 3,661).
E G nes regulated by glucose m tabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
versus G3 unpaired -test). A similar behavi r is bserved by using the YAP/TAZ signature (Cordenonsi et al, 2011). See Materials and Methods for details on the
statistical methods to quantify average signature expression. Data ar shown as mean ! standard error of the mean (SEM).
F Kaplan–Meier analy s representing the probability of m tast sis-free survival in breast cancer pa ients from the metadataset stratified according to high or low
glucose signature score. The log-rank test P-value r flects the significance of the association between high levels of the glucose signature score and shorter
urvival. A imilar behavior is obs ved by using the YAP/TAZ signa ure (Cor enonsi et al, 2011).
G Genes regulated by glucose meta olism but not by YAP/TAZ ( NOT YT signature, see Supplementary Table S5) are not expressed at higher levels in G3 grade
mammary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature expression. Data are shown
as mean ! standard erro of the mean (SEM).
H Kaplan–Mei r nalysis r presenting the probability of metast sis-free survival in breast c ncer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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Figure 6. YAP/TAZ activity is enhanced in primary human breast cancers displaying high levels of a gene signature associated to glycolysis.
A Scatter plot (gray dots) and linear regression (red line, slope 0.532) of standardized expression values indicate a positive correlation between a gene signature
experimentally associated with active glucose metabolism (glucos ) and a gene signature denoting YAP/TAZ activity, in a metadataset collecting
n = 3,661 primary human breast cancers (see Materials a d Methods). The glucose signature is composed of the genes downregulated upon 2DG treatment, that is,
requiring active gluc s metabolism for their transcription, both in MCF10A and in MDA-MB-231 cells (see Supplementary Table S5). Pearson q quantifies the linear
dependence between th levels of the two signatures. The coefficie of det rmin tion is r2 = 0.731, P-value < 0.0001.
B Primary human breast cancers of the metadataset were stratified according to high or low glucose signature score, and then, the levels of the YAP/TAZ signature
score were determined in the two groups (see Materials and Methods for details on the statistical methods to quantify scores). YAP/TAZ activity is significantly
higher in tumors with high levels f the glucose signature, a visualized by box-plot. The bot om and top of the box are the first and third quarti es, and the band
inside the box is the median; whiskers represent 1st and 99th percentiles; values lower and gr ater are shown as circles (P < 0.0001, n = 3,661).
C, D Primary human breast cancers of the metadataset were classified according to high or low glucose signature score, and then, the levels of the Staminal or stem
tumorigenic signature scores, associated to normal and cancer mammary stem cells, were determined in the two groups. Gene expression associated to mammary
stem cells is significantly higher in tumors with high levels of the glucose signature, as visualized by box-plot (P < 0.0001, n = 3,661).
E Genes regulated by glucose metabolism (glucose signature) are elevated in G3 as compared to G1 grade mammary tumors of the metadataset (P < 0.0001; G1
v sus G3 unpai d t-test). A similar behavio is obs rved by using the YAP/TAZ signature (Cordenon i et al, 2011). See Materials and Methods for details on the
statistic l meth ds o quantify average signature expression. Data re shown as me n ! stand rd error of he mean (SEM).
F Kapl –M ier analysi represe ing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified ccording to high or low
glucose signature score. Th lo -rank test P-value reflects the significance of the association between high levels of the glucose signature score and shorter
survival. A similar behavior is observed by using the YAP/TAZ sign ture (Cordenon i et al, 2011).
G Ge es regulated by gluco metabolism but not y YAP/TAZ (glucose NOT YT ignatur , s e Supplementary T ble S5) are not xpressed at higher levels in G3 grade
m mmary tumors of the metadataset. See Materials and Methods for details on the statistical methods to quantify average signature xpressio . Data are shown
as mean ! standard error of the mean (SEM).
H Kaplan–Meier analysis representing the probability of metastasis-free survival in breast cancer patients from the metadataset stratified according to high or low
glucose NOT YT signature score, which show no differences.
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FIGURE	  15.	  YAP/TAZ	  regulate	  the	  expression	  of	  multiple	  key	  enzymes	  
involved	  in	  nucleotide	  metabolism	  	  
A) The table shows the list of genes involved in nucleotide metabolism whose 
expression is inhibited upon YAP/TAZ silencing. We analyzed gene expression 
profiles carried out in 4 cell lines: MDA-MB-231 (metastatic breast cancer cells)1, 
Meso-33 (mesothelioma cells)125, HepG2 (liver hepatocellular carcinoma cells)124, 
HaCaT (keratinocyte cell line)124. Coregulated genes were identified by 
comparing control-siRNA transfected cells with YAP/TAZ-depleted cells. In 
MDA-MB-231 cells, two independent mix of YAP/TAZ siRNAs were used. The 
presence of an “x” indicates the gene is dowregulated (at least two fold) upon 
YAP/TAZ silencing. 
 
B) WI38 primary human fibroblasts cell line were infected with control (Co.), Ras 
or YAP 5SA-encoding retrovirus, or transfected with the indicated siRNAs: 
control (siCo.), YAP/TAZ (siYT). Infected cells were examined 6 days from the 
beginning of the selection, whereas transfected cells were analyzed 48h after the 
transfection. qPCR for endogenous target genes related with nucleotide 
biosynthesis showed that the expression of these genes were coherently regulated 
both by YAP/TAZ knockdown and by YAP overexpression. Ras infection serves 
as positive control121,122. Expression levels were calculated relative to GAPDH, 
and are given relative to Co. cells (arbitrarily set to 1). n=2 biological replicates 
from 2 independent experiments. 
 
C) Same samples as in (B) but examined for mRNA expression of established 
YAP/TAZ target genes53,126. These genes are YAP/TAZ targets also in WI38 cell 
line. n=2 biological replicates from 2 independent experiments. 
 
D) Western blot analysis of cell extracts infected as in (B) and probed for YAP or 
Ras, validating the overexpression. 
 
E) qPCR for endogenous mRNA levels showed efficient depletion of both YAP 
and TAZ in WI38 cells 48h after siRNA transfection. n=2 biological replicates 
from 2 independent experiments. 
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!
!! !! !!!!!!!!!!!!MDA%MB%231! Meso%33! HepG2! HaCaT!
Gene!symbol! Gene!name! siYT!1! siYT!2! siYT! siYT! siYT!
CAD! carbamoyl3phosphate!synthetase!2,!! x! x! !! !! x!
!! aspartate!transcarbamylase,!and!dihydroorotase! !! !! !! !! !!
CTPS1! CTP!synthase!1! x! x! x! !! !!
DCK! deoxycytidine!kinase! x! x! x! !! !!
DHFR! dihydrofolate!reductase! x! x! x! !! !!
DHOD! dihydroorotate!dehydrogenase!(quinone)! x! x! x! !! !!
DTYMK! deoxythymidylate!kinase!(thymidylate!kinase)! x! x! x! x! x!
IMPDH2! IMP!(inosine!5'3monophosphate)!dehydrogenase!2! x! x! !! !! !!
MTHFD! methylenetetrahydrofolate!dehydrogenase!(NADP+!dependent)!! x! x! !! !! !!
NME1! NME/NM23!nucleoside!diphosphate!kinase!1! x! x! x! !! !!
PAICS! phosphoribosylaminoimidazole!carboxylase,!! x! x! x! !! x!
!! phosphoribosylaminoimidazole!succinocarboxamide!synthetase! !! !! !! !! !!
PRPS2! phosphoribosyl!pyrophosphate!synthetase!2! x! x! !! !! x!
PSAT1! phosphoserine!aminotransferase!1! x! x! x! !! x!
RRM1! ribonucleotide!reductase!M1! x! x! x! x! x!
RRM2! ribonucleotide!reductase!M2! x! x! x! x! x!
SHMT2! serine!hydroxymethyltransferase!2!(mitochondrial)! x! x! !! !! !!
TK1! thymidine!kinase!1! x! x! x! x! x!
TYMS! thymidylate!synthetase! x! x! x! x! x!
UMPS! uridine!monophosphate!synthetase! x! x! x! !! !!
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FIGURE	  16.	  YAP	  overexpression	  is	  sufficient	  to	  overcome	  Ras-­‐induced	  
inhibition	  of	  genes	  involved	  in	  nucleotide	  metabolism	  
 
A) WI38 cells were infected with control (Co.), Ras-IRES-GFP or Ras-IRES-
YAP 5SA-encoding retrovirus. We co-expressed both Ras and constitutive active 
YAP (YAP 5SA) from the same plasmid by using an internal ribosome entry site 
(IRES) sequence. 6 days from the beginning of the selection, cells were examined 
for RNA expression. qPCR for endogenous target genes related with nucleotide 
biosynthesis showed that YAP overexpression was sufficient to reestablish the 
expression of RRM2, TK1 and TYMS to levels comparable to control cells. 
Expression levels were calculated relative to GAPDH, and are given relative to 
Co. cells (arbitrarily set to 1). n=2 biological replicates from 3 independent 
experiments. 
 
B) Same samples as in (A) but examined for mRNA expression of established 
YAP/TAZ target genes32,53. Ras activation inhibited YAP/TAZ target genes and 
YAP overexpression was able to rescue their levels. n=2 biological replicates 
from 3 independent experiments. 
 
C) qPCR for endogenous YAP or TAZ mRNA levels. Oncogenic Ras activation 
did not induce a downregulation of YAP or TAZ mRNA expression.  
 
D) Sizes of dATP, dGTP and dCTP pools in WI38 extracts infected as indicated. 
YAP overexpression rescued the levels of dATP, dGTP and dCTP. Results from 
one experiment (a new measurement is in progress).  
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FIGURE	  17.	  YAP	  overexpression	  is	  sufficient	  to	  overcome	  Ras-­‐induced	  
senescent	  phenotypes	  
 
A) WI38 cells were infected with control (Co.), Ras-IRES-GFP or Ras-IRES-
YAP 5SA-encoding retrovirus. We co-expressed both Ras and constitutive active 
YAP (YAP 5SA) from the same plasmid by using an internal ribosome entry site 
(IRES) sequence. 6 days from the beginning of the selection, cells were examined 
for RNA expression. qPCR for endogenous genes that are either induced (p21, 
p16 and p15) or inhibited (cyclin A2, cyclin B1, CDCA7) in senescent cells. YAP 
overexpression was sufficient to reestablish the expression of these markers to 
levels comparable to control cells, with the exception of p16. Expression levels 
were calculated relative to GAPDH, and are given relative to Co. cells (arbitrarily 
set to 1). n=2 biological replicates from 3 independent experiments. 
 
B) Western blot analysis of cell extracts infected as in (A) and probed for YAP or 
Ras, to validate the overexpression, or for Lamin B, RRM2 or cyclin A2, to 
examine if YAP overcame the effects of Ras infection. 
 
C) Quantification of proliferating cells, infected as in (A), measured by EdU 
incorporation (1h). YAP overexpression reestablished cell proliferation inhibited 
by Ras. Representative results of a single experiment (>350 cells per condition); 3 
independent experiments were consistent. 
 
D) Same as in (A) but cells were stained for SA-βgal activity. YAP expression 
counteracted the effects of Ras on SA-βgal activity. Representative results of a 
single experiment (>100 cells per condition); 3 independent experiments were 
consistent. 
 
E) Same as in (A) but cells were examined for SAHF formation. YAP expression 
counteracted the effects of Ras on SAHF. Representative results of a single 
experiment (>100 cells per condition); 3 independent experiments were 
consistent. 	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FIGURE	  18.	  YAP	  depletion	  induces	  senescent	  phenotypes 
 
A) Western blotting of WI38 cells transfected with the indicated siRNAs and 
probed with different antibodies. We monitored protein levels 5 days after cellular 
transfection. YAP or TAZ knockdown decreased the protein levels of RRM2, 
lamin B and cyclinA2, whose inhibitions are common in senescent cells121,127. As 
a control, YAP or TAZ were efficiently depleted from the cells. 
 
B) WI38 cells were transfected with the indicated siRNAs: control (siCo.) or YAP 
(siYAP). On day 5, proliferating cells were measured by EdU incorporation (1h). 
In absence of YAP cell proliferation was impaired. Representative results of a 
single experiment (>600 cells per condition); 2 independent experiments were 
consistent. 
 
C) Same as in (B) but cells were stained for SA-βgal activity. Representative 
result of a single experiment (>160 cells per condition); 2 independent 
experiments were consistent. 
 
D) Same as in (B) but cells were examined for SAHF formation. Representative 
result of a single experiment (>160 cells per condition); 2 independent 
experiments were consistent. 
 
E) WI38 cells were transfected with the indicated siRNAs, control (siCo.) or siYT 
(siYAP/TAZ), or infected with Ras as positive control. Ras-infected cells were 
analyzed 6 days after the selection start, whereas cells transfected with siRNAs 
were examined 48h after transfection because of the strong established effects of 
knockdown of both YAP and TAZ31. qPCR for endogenous genes that are either 
induced (p21, p16) or inhibited (cyclin A2) in senescent cells. YAP/TAZ depletion 
was sufficient to decrease the levels of cyclin A2 and to increase the CDKIs p21 
and p16.  Expression levels were calculated relative to GAPDH, and are given 
relative to Co. cells (arbitrarily set to 1). n=2 biological replicates from 2 
independent experiments. 	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